BASEL 2019

29th Regional Congress of the ISBT

In conjunction with Swiss Transfusion SRC and the Swiss Association for Transfusion Medicine

June 22 - 26, 2019 Basel, Switzerland

Final Programme



of Blood Transfusion







GET THE MOST OUT OF THE BASEL CONGRESS WITH THE ISBT APP



1531 BASEL 2019

29th Regional Congress of the International Society of Blood Transfusion, Basel, Switzerland June 22 - 26, 2019



Acknowledgements

Corporate Partners

ISBT is pleased to acknowledge the following ISBT Corporate Partners 2019-2020

GOLD













GRIFOLS

Table of Contents

١	Introduction:	
	- Words of Welcome	4
	ISBT	8
	ISBT Working Party Meetings	12
	Congress General Information	14
	General Scientific Information	16
	Posters	17
	Programme Saturday, June 22	21
	Programme Sunday, June 23	27
	Programme Monday, June 24	37
	Programme Tuesday, June 25	57
	Programme Wednesday, June 26	73
	Speakers Index	80
	Other Information	87
	– Social Programme	88
	Satallita Programmos	93
	Satellite Programmes	93
	Floor Plans	99

Word of Welcome Congress President

Dear friends and colleagues,

On behalf of Swiss Transfusion SRC and the Swiss Association for Transfusion Medicine SVTM, it is our pleasure to welcome you to the 29th Regional Congress of the International Society of Blood Transfusion in Basel, Switzerland from June 22 - 26, 2019.

The ISBT Scientific Secretary, in close collaboration with the Local Organizing Committee, will provide a broad range of topics in the scientific programme, thus offering you the opportunity to expand and update your knowledge in a number of basic as well as currently prevailing items of education, research and globalization influence in modern transfusion medicine.

Among the planned session topics are:

- Donors and donation
- Bridging the gap (plenary session)
- · Adverse events
- Big Data (plenary session)

At the same time, we want this congress to be an exciting event enabling colleagues and specialists to meet, to discuss about all the various aspects of our field of profession, to enlarge their professional network, to discover what new technologies, knowledge and findings in transfusion medicine have been acquainted.

Last but not least, we want to offer you all a good time in Basel right on the trinational border of Switzerland, Germany, and France and easily accessible via Basel Euro-Airport. The congress venue is the Basel Congress Center; it is located right in the center of this appealing international Swiss city, where you can enjoy the early summer on the river shore of the Rhine and benefit from its Mediterranean climate, a refreshing swim included.

Looking forward to meeting you here.



Rudolf Schwabe Co-Congress President Head of Local Organizing Committee ISBT 2019 Former CEO Swiss Transfusion SRC



Behrouz Mansouri Taleghani Co-Congress President Head of Local Scientific Committee ISBT 2019 Lead Consultant Transfusion Medicine and Chair Transfusion Committe Insel Group

Word of Welcome ISBT President

Dear ISBT friends and colleagues,

On behalf of the ISBT Board of Directors and our Central Office, it is my great pleasure to welcome you to the 29th Regional ISBT Congress here in Basel, Switzerland. We look forward to an exciting conference - this time in the heartland of Europe and with the Swiss Transfusion SRC and the Swiss Association for Transfusion Medicine as our hosts. Together with John Semple, our ISBT Scientific Secretary, the Local Organising Committee has put together a programme bursting with topics designed to keep us updated on the fast progress in our field.

I would like to thank Rudolf Schwabe, Chair of the Local Organising Committee and, Behrouz Mansouri Taleghani, Chair of the Local Scientific Committee, joint Congress Presidents and all their colleagues for working hard to make this a congress to remember. We start with the popular Academy Day and the science continues with invited state-of-the-art lectures covering the latest science from our field and beyond in the main programme. On top of that, your abstracts selected for oral or poster presentations will make the Congress sizzle with discoveries and late-breaking findings. In parallel, our industry partners have prepared their exhibit booths with the latest technology on offer.

We have also prepared a great Social programme like you may have experienced at previous congresses. By connecting the young and not-so-young, clinicians and scientists, transfusion practitioners and donor experts plus many other categories of delegates, we help forming the teams required to answer tomorrow's questions in transfusion medicine.

After all this, I hope that you will also find some time to explore the city and its lovely surroundings.



Martin L Olsson ISBT President

Young Professionals programme

Sunday, June 23 through Tuesday June 25
Meet and greet - Young Professionals space - 2nd floor
During refreshment breaks, come meet the Young Professionals
council members and pick up your Young Professionals pin!

Sunday, June 23 | 19:00 - 20:00 Young Professionals drinks and snacks

Come meet us at the Basement level of the Exhibition during the opening night for a drink and a snack!

Monday, June 23 | 1 07:00 - 08:30 Young Professionals breakfast - Room Samarkand

The breakfast offers the opportunity for Young Professionals to discuss their work with senior and well known transfusion medicine professionals.

You must have signed up to attend the breakfast.

Monday, June 23 | 08:30 - 10:00

Workshop on writing a successful grant application - Room Delhi Imelda Bates, Professor in Clinical Tropical Haematology at the Liverpool School of Tropical Medicine (LSTM) will share the secrets to success in obtaining grants.

Monday, June 24 I 14:00 - 15:30

Young Investigators scientific session - Room Boston

Cheer on your fellow young investigators at this special session with the highest scoring young professionals abstracts

Tuesday, June 25 | 1 | 06:30 - 07:30 | ISBT Run

Why not join the ISBT run along the river Rhine? Enjoy the Swiss fresh air and the view. Contact registration regarding signing up

Tuesday, June 25 | 08:30 - 10:00

Workshop on how to improve your scientific writing - Room Delhi Come and join this workshop led by Bob van der Laaken head of the English department at Delft University of Technology and co-author of the book Presentation Techniques. Bob will give hints and tips and more for writing abstracts and papers.

Wednesday, June 26 | 08:30 - 10:00 Pitch your research proposal - Room Samarkand

Come and support your young professional colleagues as they pitch their research proposals in front of an expert panel who will offer advice and help

WORKSHOPS

Monday, June 24 08:30 – 10:00 Room: Delhi

Fundamentals of Good Grant Writing Workshop

This workshop will be useful for those interested in applying for research grants and is designed for 'novices' as well as those with experience in grant applications. The workshop will help to improve your understanding of how to write a successful grant proposal and it will provide an opportunity to share experiences about both successful and unsuccessful grant applications. The workshop will be hosted by Imelda Bates.

Tuesday, June 25 08:30 – 10:00 Room: Delhi

Workshop on How to Improve Your Scientific Writing

A highly interactive workshop that presents a reader-centered bottom line first approach to writing scientific papers. We will, among others, answer questions like: Who is going to read this, and why? Where do I begin? Can I use "me, myself and I"? Why are there so many referencing styles? Participants are encouraged to bring their own questions and please feel free to bring a paper that you're working on.

The workshop will be hosted by Bob van der Laaken.

Wednesday, June 26 08:30 – 10:00 Room: Samarkand

Present your research idea to a panel of experts

The workshop will be hosted by Henrik Ullum and a small panel of experts. Attendees, who registered and were selected will have the possibility to present their research ideas to the panel in 5 minutes. After the presentation the expert panel will give tips and suggestions.

ISBT

An international community of professionals sharing knowledge to enhance transfusion practice.

This goal is achieved by providing many opportunities to advance knowledge and education. The membership includes transfusion medicine professionals from over 110 countries who enjoy free access to educational material via the online platform ISBT Education.

In addition ISBT:

- · Publishes two scientific journals, Vox Sanguinis and the ISBT Science Series
- · Organises international and regional congresses.
- Supports workshops, seminars and congresses globally either financially or by use of the ISBT logo.
- · Encourages and supports 14 ISBT Working Parties that focus on specific topics

ISBT Membership

As a member of ISBT you are part of a dynamic international society and enjoy the following (free) benefits:

- Access to ISBT Education (Including accredited congress webcasts and presentations)
- Access to monthly ISBT Webinars and Live Journal Clubs
- Subscription for Vox Sanguinis (paper + online)* and ISBT Science Series
- Receive quarterly society magazine Transfusion Today
- Registration discount at ISBT congresses

Take the opportunity to connect and participate in our growing transfusion medicine community and register yourself at www.isbtweb.org.

Come and meet the ISBT Central Office staff at their booth, allocated on the second floor. The staff will be happy to assist you with your registration as a new member.

^{*}Online access only for 35 years and under

Notes		

Free access to **Education Materials** Congresses **Discounts Expand your** network with colleagues and experts in your field

Hrafn Thorvaldsson Harold Gunson Fellowhip 2018

"As an ISBT member I can present my research and expand my international network meeting with people in the industry".



Become a member today and benefit from what our international community has to offer:

- Free access to ISBT Education and ISBT Education app where you'll have access to congress webcasts, presentations, past webinars, the guideline library and more educational material
- Free access to webinars and Live Journal Clubs: learn about various topics presented by experts in the field
- Registration discount for ISBT congresses
- Free access to the ISBT Forum: network with colleagues and experts in your field
- Free access to Vox Sanguinis our high impact journal and the ISBT Science Series as well as ISBT's quarterly magazine Transfusion Today

ISBT Membership Fees

	<35 years	35 - 70 years	>70 years	Allied Health Professional	Transfusion Practitioner
World Bank Index LOW	€30	€60	€45	€30	€30
LOWER MIDDLE	€30	€60	€45	€30	€30
UPPER MIDDLE	€60	€90	€60	€60	€60
HIGH	€60	€120	€90	€60	€60

ISBT Working Parties & other meetings

All meetings will take place at Congress Centre Basel (CCB), except for three WP meetings on Saturday where this is indicated

*= by invitation only Saturday, June 22

08:30 - 11:15	ISBT WP on Rare Donors	Swissôtel – Room
		Helvetia 7
08:30 - 17:30	ISBT WP on Information Technology	Mexico
09:00 - 17:00	ISBT WP on TTID*	Sydney
10:00 - 15:30	ISBT WP on Donors and Donation	Hong Kong
11:30 - 14:30	ISBT WP on Red Cell	Swissôtel - Room
	Immunogenetics and Blood Group	Helvetia 7
	Terminology	
12:00 - 15:30	ISBT WP on Global Blood Safety	Nairobi
13:00 - 16:00	ISBT WP on TTID*	Samarkand
15:00 - 18:30	ISBT WP on Immuno haematology	Swissôtel - Room
		Helvetia 7
15:00 - 18:00	ISBT WP on Clinical Transfusion*	Guanghzou
17:30 - 19:00	General Assembly SVTM - Swiss	Nairobi
	Association for Transfusion	
	Medicine*	
18:00 - 19:00	Working Party Reception	3rd Floor
Sunday, June	23	
08:30 - 17:30	ISBT WP on Information Technology	Darwin
09:00 - 10:30	ISBT WP on Haemovigilance	Boston 1
	- Recipients	
09:00 - 10:30	ISBT WP on Haemovigilance	Boston 2
	- Donors	
09:30 - 17:00	ISBT Academy I Try it 2019*	Delhi

Hong Kong

Boston 1

Boston 2

ISBT WP on Blood Supply

ISB WP on Haemovigilance

and Blood Group Terminology
International Application of Omics

Technologies in Transfusion

ISBT WP on Red Cell Immunogenetics Boston 3

Management

Medicine*

10:00 - 12:00

11:00 - 12:30

11:30 - 12:30

12:00 - 17:00

12:30 - 13:30 14:00 - 16:00 15:00 - 16:00	Harold Gunson Fellowship Lunch* Standing committee on Ethics* ISBT WP on Cellular Therapies	Samarkand Hong Kong Guangzhou
Monday, June	e 24	
07:00 - 08:15	Young Professionals Networking Breakfast	Samarkand
12:00 - 14:00	ISAC Meeting*	Samarkand
13:00 - 14:00	Young Professional Council*	Mexico
16:00 - 17:30	ISBT WP on Quality Management*	Mexico
Tuesday, Jun	e 25	
07:00 - 08:15	Presidents of the National	Samarkand
00.00 10.00	Societies Meeting*	
09:00 - 16:00	TTID MSM modelling team*	Kairo 1
12:00 - 13:00	Young Professionals Speed Dating Session*	Samarkand
13:00 - 13:45	ISBT General Assembly	Delhi
13:30 - 16:00	Standing Committee of the ISBT	Mexico
	Academy*	
14:15 - 15:00	Exhibitor Meeting	Samarkand
Wednesday, .		
12:30 - 17:00	ISBT Academy I TRY IT 2019	Mexico
13:00 - 17:00	Vox Sanguinis Editorial Board meeting*	Osaka

Congress General Information

Registration hours

The registration desk, located on the ground level of CCB, will be open as of Saturday. June 22:

Saturday	June 22	08:00 - 17:00 hours
Sunday	June 23	08:00 - 19:30 hours
Monday	June 24	08:00 - 17:00 hours
Tuesday	June 25	08:00 - 17:00 hours
Wednesday	June 26	08:00 - 13:00 hours

Exhibition hours:

Sunday	June 23	18:30 - 21:00 hours
Monday	June 24	09:00 - 16:30 hours
Tuesday	June 25	09:00 - 16:30 hours

Badges

All participants will receive a personal badge upon registration. You are kindly requested to wear your name badge at all times, during scientific meetings and social gatherings. Only participants who are wearing their name badge will be admitted to the lecture halls.

Please note: exhibitors and exhibition one-day only passes will not be admitted to the scientific sessions.

Coffee / tea breaks and Lunch

During session-breaks coffee / tea and lunch will be served free of charge in the Exhibition area to delegates wearing their name badge.

Abstract Author details

In this printed programme only the presenting author details are mentioned. For full author details on all abstracts please download the app or the Abstract Book.

EBAH Accreditation

The programme of the 29th Regional Congress of the ISBT has been reviewed and approved for CME accreditation by the European Board for Accreditation in Hematology (EBAH).

The EBAH has approved this educational activity for 27 CME credits. Each physician should only collect credits for time she/he actually spent in the educational activity.

First Aid

The First aid is located on the second floor.

Insurance

The congress organiser cannot accept responsibility for accidents that might occur. Delegates are encouraged to obtain travel insurance (medical, personal accident and luggage) in their home country prior to departure.

Internet

ISBT offers access to the WiFi network in the Congress related areas. To access the WiFi, select ISBT Basel. You will get a landing page where you need to fill in the following details:

UserID: 2254231013

Password: 4420

Language

The official Congress language will be English.

Lost and Found

Please bring any found items or collect them again at the Service desk, located in the Registration area.

Photography and Filming during the Congress

ISBT has an official photographer during the congress, capturing images. The photographs will be used by ISBT for various publications, promotional materials and on the ISBT Website. If you do not wish to appear in any images captured, please send an email to: photography@isbtweb.org

Prayer Room

The prayer room is located on the first floor, in the back of the Poster Area.

Staff

If you have any questions, the members of the congress staff, who can be recognized by their blue ISBT shirts, will be very pleased to assist you. Please do not hesitate to contact them if you have any questions.

General Information regarding the Scientific Programme

Important Notice for Moderators and Speakers

All moderators and speakers are kindly requested to be in the session room at least 15 minutes before the beginning of the session.

Photographing and videoing during sessions is not allowed

Materials contained in ISBT Congress presentations, including slides and abstracts are protected by copyright. Any photography, filming, or audio-video recording of the presentations is strictly prohibited.

Abstracts

Abstracts are printed in a supplement of Vox Sanguinis. All abstracts are listed in the online Programme Book, available online at the Congress Website and the ISBT Congress Mobile Application.

ISBT Science Series

The Science Series containing the State of the Art Papers accompanying the 29th Regional congress, will be available online by the end of the year.

Certificates of Attendance

Certificates of Attendance will be sent by email, shortly after the congress.

Speaker Ready Room

The Speaker Ready Room (SRR) is located in Meeting Room Rio (second floor). Speakers are requested to bring their presentation to the Speaker Ready Room on an USB stick at least 1 hour prior to their session starts. You may also bring your laptop for copying your presentation to the main computer, which will be used for sending the presentations to the different meeting rooms. The use of your own laptop during your presentation is NOT possible.

The opening hours of the SRR are:

Saturday	June 22	08:00 - 17:00 hours
Sunday	June 23	08:00 - 17:00 hours
Monday	June 24	08:00 - 17:00 hours
Tuesday	June 25	08:00 - 17:00 hours
Wednesday	June 26	08.00 - 12:00 hours

Programme changes

The organisers cannot assume liability for any changes in the programme due to external or unforeseen circumstances.

Posters

Poster Area

All accepted posters (publication and display) will be presented in Hall 4.1 on the second floor, next to the exhibition area. A list of the posters on display can be found on the next page, in the online congress Abstract book and via the Mobile Application. The posters are set out according to the topic and the number of the abstract is displayed in the Mobile application and on the poster board. Posters will be on display in the poster area for 3 days.

Poster Mounting

Posters can be mounted as of Sunday, June 23 at 08:00 hours.

- The number of your poster can be found in the (online) Abstract book and the Mobile Application.
- Posters should be mounted with double sided tape only. Assistance and
 material for mounting the posters will be available from set-up time, at the
 poster desk in the poster area.

Opening hours Poster desk:

Sunday	June 23	08:00 - 21:00 hours
Monday	June 24	09:00 - 16:30 hours
Tuesday	June 25	09:00 - 18:30 hours

Poster Session

The Poster Session will be organised on Tuesday June 25, from 17:30 - 18:30 hours. All Poster authors are kindly requested to be present at their poster during the entire session.

The Poster session will be held to enable poster presenters to showcase their work. All delegates are invited to walk around the poster area to view the posters and to enter into lively and challenging discussions with the poster presenters. Snacks and drinks will be served.

Poster Material Removing

Material should be taken before Tuesday, June 25 at 18:30 hours. Material that has not been taken down by the author(s) by this time will be removed and disposed.

Responsibility for poster presentations

The ISBT and the Local Organising Committee do not assume any responsibility for material displayed on the poster boards.

Posters

1.0 1.1 1.2 1.3 1.4 1.5 1.6	Management and Organisation Organisational issues Information technology Cost/effectiveness Training and education Risk models, standards and regulation Blood supply management and utilization Quality management	P-001 - P-011 P-012 - P-016 P-017 - P-018 P-019 - P-023 P-024 - P-026 P-027 - P-046 P-047 - P-058
2.0 2.1 2.2 2.3	Blood donation Blood donor recruitment Blood collection including apheresis Donor adverse events	P-059 - P-090 P-091 - P-105 P-106 - P-123
3.0 3.1 3.2 3.3 3.4 3.5	Blood products Blood processing, storage and release Blood components Plasma products Pathogen inactivation Novel blood products	P-124 - P-154 P-155 - P-179 P-180 - P-184 P-185 - P-199 P-200 - P-215
4.0 4.1 4.2 4.3 4.4 4.5 4.6 4.7	Transfusion transmitted infections Screening strategies for TTI Hepatitis B (HBV) Hepatitis C (HCV) HIV Bacteria Parasites Newly emerging pathogens and other transfusion related pathogens	P-216 - P-259 P-260 - P-267 P-268 - P-273 P-274 - P-279 P-280 - P-293 P-294 P-295 - P-303
5.0 5.1 5.2 5.3 5.4 5.5	Immunohaematology Red cell immunology: Serology Red cell immunology: Molecular Platelet immunology Granulocyte immunology Fetal-maternal immunology	P-304 - P-354 P-355 - P-412 P-413 - P-424 P-425 - P-427 P-428 - P-448

Posters

6.0	Clinical transfusion	
6.1	Neonatal and pediatric transfusion	P-449 - P-454
6.2	Therapeutic apheresis	P-455 - P-473
6.3	Evidence based transfusion medicine practice	P-474 - P-503
6.4	Haemorrhage and massive transfusion	P-504 - P-514
6.5	Adverse events, including TRALI	P-515 - P-524
6.6	Haemovigilance and transfusion safety	P-525 - P-535
6.7	Alternatives to blood transfusion	P-536 - P-537
7.0	Cellular therapies	
7.1	Stem cell and tissue banking, including	
	cord blood	P-538 - P-542
7.2	Collection, processing, storage and release	P-543 - P-553
7.3	Clinical applications	P-554 - P-560
8.0	Clinical immunogenetics	
8.2	Histocompatibility in stem cell transplantation	P-561 - P-563
8.3	Histocompatibility in organ transplantation	P-564



GET TRANSFUSION MEDICINE EDUCATION ANYTIME ANYWHERE

on your desktop or mobile device



Scan the QR code with your phone camera



All the educational content about Transfusion Medicine in just 1- Click!



Programme at a Glance Local/Neighbours Day Saturday, June 22

	Montreal
09.00 - 10.30	1A-01 Innovation in Austria
10.30 - 11.00	Coffee Break
11.00 - 12.30	18-02 Innovation in France
12.30 - 13.30	Lunch
13.30 - 15.00	1C-03 Innovation in Germany
15.00 - 15.30	Coffee Break
15.30 - 17.00	ID-04 Innovation in Switzerland

09:00 - 10:30 Room: Montreal

Local/Neighbours Day: Innovation in Austria

Moderators: G. Leitner (Austria) and C. Gabriel (Austria)

09:00 - 09:30 SOUND OF MUSIC: QUANTUM MECHANICS OF INNOVATION

1A-01-01 IN AUSTRIA

C. Gabriel

Medical University Graz, Graz, Austria, Ludwig Boltzmann Society,

Vienna, Austria

09:30 - 10:00 INNOVATION IN CELLULAR THERAPY: HYPE AND HOPE

1A-01-02 N. Worel

Medical University Vienna, Vienna, Austria

10:00 - 10:30 INFLUENCE OF ANEMIA ON OUTCOME IN PATIENTS
1A-01-03 UNDERGOING ORTHOTOPIC LIVER TRANSPI ANTATION

D. Baron

Medical University of Vienna, Vienna, Austria

10:30 - 11:00 Coffee Break

11:00 - 12:30 Room: Montreal

Local/Neighbours Day: Innovation in France

Moderator: P. Tiberghien (France)

11:00 - 11:30 TRANSFUSION MEDICINE FOR SICKLE CELL PATIENTS: FROM

1B-02-01 BLOOD DONOR ACCRUAL TO GENE THERAPY

F. Pirenne

Etablissement Français du Sang, Créteil, France

11:30 - 12:00 IMMUNOTHERAPY CART-CELLS: FROM TARGET

1B-02-02 IDENTIFICATION TO THE CLINIC

C. Ferrand

INSERM UMR1098 - EFSBFC - UBFC, Besancon Cedex, France

12:00 - 12:30 TRANSFUSION IN THE ACUTE BLEEDING SETTING: MASSIVE TRANSFUSION PROTOCOLS. INTRODUCING NEW "OLD" BLOOD

PRODUCTS SUCH AS WHOLE BLOOD

S. Ausset

Val de Grâce Military Medical Academy, Paris, France

12:30 - 13:30 Lunch

13:30 - 15:00 Room: Montreal

Local/Neighbours Day: Innovation in Germany

Moderator: B. Mansouri (Switzerland)

13:30 - 14:15 MESENCHYMAL STROMAL CELLS FOR REGENERATIVE

1C-03-01 THERAPY

H. Schrezenmeier

 ${\sf DRK\text{-}Blutspendedienst\ Baden\text{-}W\"{u}rttemberg\text{ - Hessen,\ UIm,}}$

Germany

14:15 - 15:00 IN VITRO PRODUCTION OF MEGAKARYOCYTES

1C-03-02 C. Figueiredo

Hannover Medical School, Hannover, Germany

15:00 - 15:30 Coffee Break

15:30 - 17:00 Room: Montreal

Local/Neighbours Day: Innovation in

Switzerland

Moderators: A. Buser (Switzerland) and S. Amar (Switzerland)

15:30 - 16:00 WE ARE STARDUST - WHAT COMETS TELL US ABOUT OUR

1D-04-01 ORIGINS

K. Altwegg

University of Bern, Bern, Switzerland

16:00 - 16:30 THE SKY'S THE LIMIT – NEXT GENERATION ENGINEERED

1D-04-02 CELLULAR THERAPIES

L. Jeker

Basel University Hospital and University of Basel, Basel,

Switzerland

16:30 - 17:00 CELL-FREE NUCLEIC ACIDS IN TRANSFUSION MEDICINE

1D-04-03 S. Waldvogel

University Hospital of Geneva, Geneva, Switzerland

Programme at a Glance Academy Day Sunday, June 23

	Montreal	Sydney				
09:00 - 10:30	2A-01	2A-02				
	Various Facets of Donor Management Transfusion Challenges in Patients with Sickle- Disease					
10:30 - 11:00	Break					
11:00 - 12:30	2B-03	2B-04				
	Artificial Intelligence and Ethics	Issues around Transfusion in Infants and Children				
12:30 - 13:30	Lunch					
13:30 - 15:00	2C-05	2C-06				
	Management of Transfusion- transmitted Infections	Immunohaematology				
15:00 - 15:30	Coffee Break					
15:30 - 17:00	2D-07	2D-08				
	Novel Technologies for Transfusion Medicine	Platelet and Granulocyte immunology				
17:30 - 18:30	Opening Ceremony (Plenary Room: San Francisco)					
18:30 - 21:00	Opening of the Trade Exhibition and Welcome Reco	eption				

09:00 -Room:

Sunday, June 23

09:00 - 10:30 Room: Montreal

Academy Day: Various Facets of Donor Management

Moderators: M. Goldman (Canada) and K. Magnussen (Denmark)

09:00 - 09:30 IMPACT OF BLOOD DONATION ON EXERCISE TOLERANCE

2A-01-01 J. W. Helge

University of Copenhagen, Copenhagen, Denmark

09:30 - 10:00 HOW DOES DEFERRAL IMPACT THE BLOOD DONOR?

2A-01-02 T. E. Davison

Australian Red Cross Blood Service, Melbourne, Australia

10:00 - 10:30 THE GIFT OF LIFE - DOES IT APPLY TO DONATION FOR

2A-01-03 RESEARCH?

V. Raivola

Finnish Red Cross Blood Service, Helsinki, Finland

10:30 - 11:00 Coffee Break

09:00 - 10:30 Room: Sydney

Academy Day: Transfusion Challenges in

Patients with Sickle Cell Disease

Moderators: T. Peyrard (France) and N. Thornton (United Kingdom)

09:00 - 09:30 IMMUNOHAEMATOLOGICAL FEATURES OF PATIENTS WITH

2A-02-01 SICKLE CELL DISEASE

V. Thonier

Institut National de la Transfusion Sanguine, Paris, France

09:30 - 10:00 PHENOTYPE AND ALLELE MATCHING: HOW FAR SHOULD WE

2A-02-02 GO?

C. Folman

Sanguin Diagnostic Services, Amsterdam, Netherlands

10:00 - 10:30 MANAGEMENT OF DELAYED HEMOLYTIC TRANSFUSION

2A-02-03 REACTIONS AND HYPERHEMOLYSIS SYNDROME

S. Trompeter

University College London NHS Foundation Trust, London, United

Kingdom

10:30 - 11:00 Coffee Break

11:00 - 12:30 Room: Montreal

Academy Day: Artificial Intelligence and Ethics

Moderators: G. Clarke (Canada) and S. Allard (United Kingdom)

11:00 - 11:45 THE USE OF ARTIFICIAL INTELLIGENCE TO IMPROVE HEALTH
28-03-01 CARE: WHAT'S IN IT FOR TRANSFUSION MEDICINE?

B. Geerts

Amsterdam UMC, Amsterdam, Netherlands

11:45 - 12:30 BLOOD DONATION: INCENTIVES AND INDUCEMENTS - WHERE

2B-03-02 TO DRAW THE LINE?

P. Flanagan

New Zealand Blood Service, Wellington, New Zealand

12:30 - 13:30 Lunch



11:00 - 12:30 Room: Sydney

Academy Day: Issues around Transfusion in Infants and Children

Moderator: M. Badawi (Saudi Arabia)

11:00 - 11:30 PLATELET TRANSFUSION TRIGGERS IN NEONATES

2B-04-01 <u>E. Lopriore</u>

LUMC, Leiden, Netherlands

11:30 - 12:00 DIAGNOSING TACO IN CHILDREN

2B-04-02 F. Gauvin

CHU Sainte-Justine, Montreal, Canada

12:00 - 12:30 APPLYING PATIENT BLOOD MANAGEMENT (PBM) PRINCIPLES

2B-04-03 IN PAEDIATRIC PATIENTS

G. Crighton

Royal Children's Hospital, Melbourne, Australia

12:30 - 13:30 Lunch

Sunday, June 23 13:30 - 15:00



Room: Montreal

Academy Day: Management of Transfusion-transmitted Infections

Moderators: M. Satake (Japan) and J. Levi (Brazil)

13:30 - 14:00 2C-05-01

A RISK-BASED DECISION-MAKING FRAMEWORK FOR BLOOD SAFETY: WHAT'S THE CASE FOR 7IKA?

E. Bloch

Johns Hopkins University School of Medicine, Baltimore, United States

14:00 - 14:30 2C-05-02

SCREENING STRATEGIES TO MINIMIZE THE RISK OF TT-HEV INFECTIONS

T. Vollmer

Institut für Laboratoriums- und Transfusionsmedizin. Herz- und Diabeteszentrum Nordrhein-Westfalen. Universitätsklinik der Ruhr-Universität Bochum, Bad Oevnhausen, Germany

14:30 - 15:00 20-05-03

UPDATE ON PATHOGEN INACTIVATION TECHNOLOGY

M. Lozano

University Clinic Hospital, Barcelona, Spain

15:00 - 15:30 Coffee Break

13:30 - 15:00 Room: Sydney

Academy Day: Immunohaematology

Moderators: C. Lomas-Francis (United States) and M. de Haas (Netherlands)

13:30 - 14:00 P1PK: A BLOOD GROUP SYSTEM WITH AN IDENTITY CRISIS

2C-06-01 Å. Hellberg

Clinical Immunology and Transfusion Medicine, Lund, Sweden

14:00 - 14:30 WHY ARE THE GATA AND KLE REGULATOR GENES INCLUDED

2C-06-02 IN THE BLOOD GROUP TABLES?

N. Nogues

Banc de Sang i Teixits, Barcelona, Spain

14:30 - 15:00 CELL-FREE FETAL DNA FOR FETAL BLOOD GROUP 2C-06-03 GENOTYPING: NON-INVASIVE PRENATAL TESTING

F. B. Clausen

Copenhagen University Hospital, Copenhagen, Denmark

15:00 - 15:30 Coffee Break

Sunday, June 23

15:30 - 17:00 Room: Montreal

Academy Day: Novel Technologies for

Transfusion Medicine

Moderators: E. Jansen (Netherlands) and S. Goudar (United States)

15:30 - 16:00 IT IN BLOOD BANKS, PRESENT AND FUTURE, A NORDIC

2D-07-01 PERSPECTIVE H. G. Jensen

Aarhus University Hospital, Aarhus N. Denmark

APPLYING DRONES TO SUPPLY BLOOD TO REMOTE AREAS: 16:00 - 16:30

2D-07-02 RWANDA'S EXPERIENCE

S. Gatare

Rwanda-Ministry of Health-National Blood Services, Kigali. Rwanda

NOVEL CHALLENGES IN BLOOD INVENTORY MANAGEMENT. 16:30 - 17:00 2D-07-03

AND BEDSIDE TRANSFUSION L. Lodge

Scottish National Blood Transfusion Service, Edinburgh, United Kingdom

Opening Ceremony (Plenary Room: San Francisco) 17:30 - 18:30

Opening of the Trade Exhibition and Welcome Reception 18:30 - 21:00

During the official opening of the Trade Exhibition there will be entertainment offered at various stands on both exhibition floors.

18:45 - 19:00 1st floor Ortho Diagnostics (1431) 19:00 - 19:15 Basement MacoPharma (U302)

Wuhan BMS Medicaltech Co., LTD (U123) 19:15 - 19:30 Basement

19:30 - 19:45 Basement Bio-Rad (U311) 19.45 - 20.00 1st floor Immucor (1215) 20:00 - 20:15 Basement

Sato Corporation (U104)

Sunday, June 23

15:30 - 17:00 Room: Sydney

Academy Day: Platelet and Granulocyte

Immunology

Moderators: Y.L. Fung (Australia) and A. Wikman (Sweden)

15:30 - 16:00 WORK-UP IN CASE OF GRANULOCYTE ANTIBODIES

2D-08-01 B. K. Flesch

DRK Blutspendedienst West, Bad Kreuznach, Germany

16:00 - 16:30 OPTIMAL ALGORITHMS FOR SEROLOGICAL AND MOLECULAR

2D-08-02 TYPING IN PLATELET ALLOANTIBODY INVESTIGATIONS M. T. Ahlen

University Hospital of North Norway, Tromso, Norway

16:30 - 17:00 MOLECULAR BASIS OF HNA-2 EXPRESSION

2D-08-03 B. Bayat

Institute for Clinical Immunology and Transfusion Medicine,

Giessen, Germany

17:30 - 18:15 Opening Ceremony (Plenary Room: San Francisco)

18:15 - 21:00 Opening of the Trade Exhibition and Welcome Reception

During the official opening of the Trade Exhibition there will be entertainment offered at various stands on both exhibition floors:

19:15 - 19:30 Basement Wuhan BMS Medicaltech Co., LTD (U123)

 19:30 - 19:45
 Basement
 Bio-Rad (U311)

 19:45 - 20:00
 1st floor
 Immucor (1215)

 20:00 - 20:15
 Basement
 Sato Corporation (U104)

Programme at a Glance Monday, June 24

Plenary Session
Blood Products
Clinical
Cellular Therapies
Donors / Donation
Adverse events
Immunobiology of Blood Cells
Management & Organization
Other Sessions

	San Francisco	Montreal	Sydney	Boston	Shanghai	Delhi	Samarkand
07:00 - 08:15							Young Profes- sionals Networking Breakfast Session
08:30 - 10:00	3A-S01 Clinical Transfusion I	34-502 Blood Group Genomics: A Debate	3A-S03 Blood Safety from the Perspective of the Vironne	3A-S04 Blood Component Issues	3A-S05 Reach and Retain Donors in Low, Medium and High Income Settings	Fundamentals of Good Grant Writing Workshop	
10:00 - 10:30				Visit the Exhibition and Coffee Break	e Break		
10:30 - 12:00	PL-01 Plenary Session Bridging the Gap						
12:00 - 14:00			Visit the Exhib	Visit the Exhibition, Lunch and Satellite Symposia	llite Symposia		
14:00 - 15:30	3C-SO6 Genotyping	3C-S07 Focus on Pediatrics	3C-S08 TTI, Immune Interactions and Risk	3C-S09 Young Investiga- tors - Excellence in Transfusion	3C-S10 Blood Donor Retention & the Role of Side Effects	3c-TP01 Anaemia management - The importance of the Transfusion Practitioner in the multidisciplinary team	
15:30 - 16:00			Visit the	Visit the Exhibition and Coffee Break	e Break		
16:00 - 17:30	30-\$11	3D-S12	3D-S13	3D-S14	30-815		
	Red Blood Cell Destruction and Immune Regulation	Haemoglobino- pathies; State of the Art	Update on Retroviruses in Transfusion Medicin	Improving Transfusion Organisation and Practice	Blood Donation; Iron Loss; Anemia and Beyond		

07:00 - 08:15

Room: Samarkand

Young Professionals Networking Breakfast Session

Pre-registration is required to attend this session

Young Professionals Networking Breakfast Session Pre-registration is required to attend this session

This breakfast session is a great opportunity for young professionals, who are 40 years old or less to meet and talk to transfusion medicine experts, who will be available to discuss the challenges and joys of their field and to give tips and suggestions.

The breakfast will take place in an informal setting. Please note that to attend this session, you need to have a good understanding of and be able to express yourself in English.

08:30 - 10:00 Room: Delhi

Fundamentals of Good Grant Writing Workshop

This workshop will be useful for those interested in applying for research grants and is designed for 'novices' as well as those with experience in grant applications. The workshop will help to improve your understanding of how to write a successful grant proposal and it will provide an opportunity to share experiences about both successful and unsuccessful grant applications.

The workshop will be hosted by Imelda Bates.

08:30 - 10:00

Plenary Room: San Francisco

Clinical - Clinical Transfusion I

Moderators: S. Allard (United Kingdom) and A. Buser (Switzerland)

08:30 - 08:45 GETTING WISE WITH ABO-INCOMPATIBLE LIVE RELATED. 3A-S01-01 RENAL TRANSPLANT: A TERTIARY CENTER EXPERIENCE

S. Agrawal

Indraprastha Apollo Hospital, New Delhi, India

08:45 - 09:00 DEVELOPMENT OF DETAILED TRANSFUSION EXPOSURE

3A-S01-02 INFORMATION FROM PATIENT FLECTRONIC HEALTH RECORDS.

USING NATURAL LANGUAGE PROCESSING

B. I. Whitaker

U.S. Food & Drug Administration, Silver Spring, MD, United States

09:00 - 09:15 RHD IMMUNOGLOBULIN: ARE WE GETTING IT RIGHT IN

3A-S01-03 OBSTETRICS? L. Bielby

Australian Red Cross Blood Service, Melbourne, Australia

09:15 - 09:30 THE FEFECT OF INTRAUTERINE TRANSFUSION ON FETAL 3A-S01-04 RETICULOCYTE COUNTS AND OUTCOME IN ALLOIMMUNE

HEMOLYTIC DISEASE OF THE FETUS AND NEWBORN I. M. C. Ree

Sanguin, Leiden, Netherlands, Leiden University Medical Center, Leiden. Netherlands

09:30 - 09:45 IDARUCIZUMAB FOR DABIGATRAN REVERSAL - A SINGLE-3A-S01-05 CENTER ANALYSIS OF TWO YEARS' EXPERIENCE

B. Lima Pinto

Centro Hospitalar e Universitário de São João. E.P.E.. Porto.

Portugal

09:45 - 10:00 PATHOGEN REDUCTION OF FROZEN PLATELETS

3A-S01-06 D. Kutac

Central Military Hospital Prague, Prague, Czech Republic, Faculty of Military Health Sciences, University of Defence Hradec Kralove, Hradec Kralove, Czech Republic

08:30 - 10:00 Room: Montreal



Immunobiology - Blood Group Genomics: A Debate

Joint ISBT/AABB session

Moderators: M. Keller (United States) and B. Frey (Switzerland)

08:30 - 09:00 3A-S02-01 PHENO AND GENOTYPE IN BLOOD GROUP TYPING – TWO

SIDES OF THE COIN - PART I

C. M. Westhoff

New York Blood Center, New York, United States

09:00 - 09:30 3A-S02-02

09:00 - 09:30 PHENO AND GENOTYPE IN BLOOD GROUP TYPING - TWO

SIDES OF THE COIN - PART II

C. Gassner

Independent Researcher, Zurich, Switzerland

09:30 - 09:45 3A-S02-03 RHEFERENCE DATABASE: THE COMPREHENSIVE DATABASE

FOR RHD VARIANTS

A. Floch

French Blood Agency, Creteil, France, Labex GR-Ex, Paris, France

09:45 - 10:00 3A-S02-04 AUTOMATED TYPING OF COMPLEX RH GENOTYPES FROM

WHOLE GENOME SEQUENCES

W. Lane

Brigham and Women's Hospital, Boston, United States, Harvard

Medical School, Boston, United States

08:30 - 10:00 Room: Sydney

Adverse Events - Blood Safety from the Perspective of the Virome

Moderators: M. Schmidt (Germany) and C. Niederhauser (Switzerland)

08:30 - 09:00 METAGENOMICS AND BLOOD-DERIVED PRODUCTS

3A-S03-01 O. Preynat-Seauve

Geneva University Hospitals, Geneva, Switzerland

09:00 - 09:15 MOLECULAR- AND IMMUNO- MAGNETIC AGGLUTINATION

3A-S03-02 ASSAYS ON A SINGLE ANALYTICAL PLATFORM: APPLICATION

TO DIAGNOSIS OF ARBOVIRAL INFECTIONS

C. Fournier-Wirth

Etablissement Français du Sang, Montpellier, France

09:15 - 09:30 ZIKA, CHIKUNGUNYA, AND DENGUE VIRUS INCIDENCE IN

3A-S03-03 BLOOD DONORS IN BRAZIL 2016-2018

B. Custer

Vitalant Research Institute, San Francisco, United States

09:30 - 09:45 VECTOR-BORNE DISEASES AND BLOOD TRANSFUSION SAFETY:

3A-S03-04 A EUROPEAN PERSPECTIVE

R. C. Garzon Jimenez

Sanguin, Amsterdam, Netherlands

09:45 - 10:00 APPLICATION OF A ZIKA VIRUS SEROLOGICAL ASSAY TO

3A-S03-05 FVALUATE INFECTION RATES IN DONORS FOLLOWING THE

2016 EPIDEMIC IN PUERTO RICO

M. Busch

Vitalant Research Institute, San Francisco, United States, University of California, San Francisco, United States

08:30 - 10:00 Room: Boston

Blood Products - Blood Component Issues

Moderators: R. Cardigan (United Kingdom) and D. Goslings (Switzerland)

08:30 - 09:00 BENEFITS OF THAWED PLASMA IN BLOOD SUPPLY

3A-S04-01 MANAGEMENT J. J. Zwaginga

<u>J. J. Zwagiliga</u>

Leiden University Medical Center, Leiden, Netherlands, Sanquin

Research, Leiden, Netherlands

09:00 - 09:15 CHALLENGING THE 30-MINUTE RULE FOR THAWED PLASMA

3A-S04-02 S. Ramirez-Arcos

Canadian Blood Services, Ottawa, Canada

09:15 - 09:30 SEX HORMONE INTAKE IN FEMALE BLOOD DONORS

3A-S04-03 MODULATES RED BLOOD CELL SUSCEPTIBILITY TO

SPONTANEOUS AND STRESS-INDUCED HEMOLYSIS DURING COLD STORAGE

T. Kanias

Vitalant, Denver, United States

09:30 - 09:45 DEHT PLASTICIZER PRESERVES RED BLOOD CELL QUALITY

3A-S04-04 WELL DURING STORAGE IN PVC BLOOD BAGS

L. Larsson

Karolinska University Hospital, Stockholm, Sweden, Karolinska

Institutet, Stockholm, Sweden

09:45 - 10:00 PROTEASOME MODULATION IN STORED RBCS: STORAGE AGE

3A-S04-05 AND DONOR EFFECTS

V. Tzounakas

National and Kapodistrian University of Athens, Athens, Greece

08:30 - 10:00 Room: Shanghai

Donors and Donation - Reach and Retain Donors in Low, Medium and High Income Settings

Moderators: S.-Y. Kwon (Korea) and R. Schwabe (Switzerland)

08:30 - 09:00 REACH AND RETAIN DONORS IN RESOURCE POOR SETTINGS

3A-S05-01 L. Indermuehle

Swiss Red Cross, Wabern, Switzerland

09:00 - 09:15 RECRUITMENT OF FUTURE BLOOD DONORS FOR SUPPLYING
3A-S05-02 THE SAFEST BLOOD AND NATIONAL SELF SUFFICIENCY OF

BLOOD SUPPLY

T. Ilbars

Ministry of Health, Ankara, Turkey

09:15 - 09:30 EFFECTIVE METHODS FOR REACTIVATING INACTIVE BLOOD

3A-S05-03 DONORS: A STRATIFIED RANDOMIZED CONTROLLED STUDY

J. Ou-Yang

Guangzhou Blood Center, Guangzhou, China

09:30 - 09:45 PROMOTION OF VOLUNTARY BLOOD DONATIONS IN PAKISTAN
3A-S05-04 THROUGH THE FACEBOOK BLOOD DONATION FEATURE

H. A. Zaheer

Ministry of National Health Services, Government of Pakistan,

Islamabad, Pakistan

09:45 - 10:00 RECRUITMENT OF BLOOD DONORS OF NON-CAUCASIAN
3A-S05-05 ETHNICITY: THE EXPERIENCE OF A SWISS BLOOD DONATION

CENTER T. Ruefli

Blood Donation Center Swiss Red Cross Basel, Switzerland

10:30 - 12:00

Plenary Room: San Francisco

Plenary Session: Bridging the Gap

Moderators: I. Bates (United Kingdom) and S. Amar (Switzerland)

10:30 - 11:00 TRANSFUSION AND TREATMENT OF SEVERE ANAEMIA IN

L-01-01 AFRICAN CHILDREN TRIAL (TRACT)

K. Maitland

KEMRI Wellcome Trust Research Programme, Kilifi, Kenya,

Imperial College, London, United Kingdom

11:00 - 11:30 GLOBAL PERSPECTIVE OF ETHICS IN HEALTH SUPPLY

PL-01-02 - CRITICAL APPRAISAL

S. Hurst Majno

University of Geneva, Geneva, Switzerland

11:30 - 12:00 TRANSFUSION IN LIMITED INFRASTRUCTURE LOCATIONS

PL-01-03 A. Greinacher

University Medicine, Institute for Immunology and Transfusion

Medicine, Greifswald, Germany

12:00 - 14:00 Visit the Exhibition, Lunch and Satellite Symposia

14:00 - 15:30

Plenary Room: San Francisco

Immunobiology - Genotyping

Moderators: J. Storry (Sweden) and C. Gassner (Switzerland)

14:00 - 14:30 HLA- AND BLOODGROUP-TYPING WITH NGS - ONE-STOP SHOP

3C-S06-01 G. Schöfl

DKMS Life Science Lab. Dresden, Germany

14:30 - 14:45 A CUSTOMISABLE, COMPREHENSIVE SEQUENCING PANEL FOR

3C-S06-02 RED CELL, PLATELET AND NEUTROPHIL GENOTYPING F Roulis

Australian Red Cross Blood Service, Kelvin Grove, Australia

14:45 - 15:00 DONOR CHARACTERISATION: A NOVEL PLATFORM FOR

3C-S06-03 COMPREHENSIVE GENOTYPING, RESULTS FROM A LARGE-

SCALE STUDY N. Gleadall

University of Cambridge, Cambridge, United Kingdom, NHS Blood

and Transplant, Cambridge, United Kingdom

15:00 - 15:15 FULL BLOOD GROUP GENOTYPE PROFILE BY NATIONAL 30-\$06-04 BIOBANK WHOLE-GENOME SEQUENCING ANALYSIS

<u>P. C. Wu</u>

Taipei Blood Center, Taipei, Taiwan - China

15:15 - 15:30 EXTENDED BLOOD GROUP GENOTYPING OF IMMORTALISED 3C-S06-05 ERYTHROID CELL LINE BEL-A2 USING NEXT GENERATION

WHOLE EXOME SEQUENCING

R. Javed

University of Bristol, Bristol, United Kingdom, TATA Medical

Center, Kolkata, India

14:00 - 15:30 Room: Montreal

Clinical - Focus on Pediatrics

Moderators: J. Hendrickson (United States) and J. Rössler (Switzerland)

14:00 - 14:30 ITP TREATMENT IN PAEDIATRIC PATIENTS

3C-S07-01 S. Holzhauer

Charité - Universitätsmedizin Berlin, Berlin, Germany

14:30 - 14:45 INTERNATIONAL VARIATION IN PLATELET TRANSFUSIONS

3C-S07-02 PRACTICES AMONG CRITICALLY ILL CHILDREN

M. Nellis

Weill Cornell Medicine, New York, United States

14:45 - 15:00 PROPHYLACTIC PLATELET TRANSFUSION IN PEDIATRIC
3C-S07-03 PATIENTS WITH CANCERS: BAMBINO GESU' CHILDREN'S

HOSPITAL EXPERIENCE

P. Berti

IRCCS Bambino Gesu' Children's Hospital, Rome, Italy

15:00 - 15:15 THE RESULTS OF TRANSFUSIONS OF PATHOGEN-REDUCED 3C-S07-04 RED BLOOD CELL SUSPENSIONS IN CHILDREN WITH

RED BLOOD CELL SUSPENSIONS IN CHILDREN WITH ONCOLOGICAL AND HEMATOLOGICAL DISEASES

I. Kumukova

National Medical Research Center for Pediatric Hematology,

Oncology and Immunology, Moscow, Russia

15:15 - 15:30 5-YEAR ¬TEMPORAL TRENDS IN PERIOPERATIVE RED CELL 3C-\$07-05 TRANSFUSIONS IN CHILDREN: NATIONALLY REPRESENTATIVE

DATA FROM A LARGE PROSPECTIVE NORTH AMERICAN

REGISTRY A. Gupta

Vanderbilt University, Nashville, United States

14:00 - 15:30 Room: Svdnev

Adverse Events - TTI. Immune Interactions and Risk

Moderators: S. Sauleda (Spain) and J. Gottschalk (Switzerland)

14:00 - 14:30 TTI AND PATIENTS WITH IMMUNE DEFICIENCY: SELECTED

3C-S08-01 BLOOD PRODUCTS OR CLOSE MONITORING

H. Hirsch

University of Basel, Basel, Switzerland

14:30 - 14:45 CHARACTERIZATION OF HEPATITIS B VIRUS STRAINS

3C-S08-02 INFECTING BLOOD DONORS WITH HIGH HBSAG LEVELS AND

INCONSISTENTLY DETECTABLE HBV DNA: IMPLICATIONS FOR

BLOOD SAFETY AND SCREENING POLICY

D. Candotti

National Institute of Blood Transfusion, Paris, France

14:45 - 15:00 HEPATITIS B VIRUS INFECTION AFTER VACCINATION IN A

3C-S08-03 BLOOD DONOR: A CASE REPORT

A. Brassel

Interregional Blood Transfusion SRC, Bern, Switzerland

ANALYSIS OF SERUM HEPATITIS B CORE-RELATED ANTIGEN 15:00 - 15:15 3C-S08-04 (HBCRAG) IN BLOOD DONORS WITH OCCULT HEPATITIS B.

VIRUS INFECTION

M. Spreafico

Azienda Socio-Sanitaria Territoriale (ASST) di Lecco, Lecco, Italy

15:15 - 15:30 ANALYSIS OF T CELL IMMUNOLOGICAL CHARACTERISTICS OF 3C-S08-05

OCCULT HEPATITIS B INFECTION

X. Rong

Guangzhou Blood center, Guangzhou, China, Southern Medical

University, Guangzhou, China

14:00 - 15:30 Room: Boston

Young Investigators - Excellence in Transfusion

Moderators: M.L. Olsson (Sweden) and J.W. Semple (Sweden)

14:00 - 14:15 3C-S09-01 DEVELOPMENT OF SCENARIOS FOR THE FUTURE DEMAND OF BLOOD PRODUCTS IN THE NETHERLANDS: SCENARIO SESSIONS

P. Langi Sasongko

Sanquin, Amsterdam, Netherlands

14:15 - 14:30 3C-S09-02 POLYGENIC RISK SCORES BASED ON PLASMA FERRITIN DO NOT PREDICT TIREDNESS/LACK OF ENERGY IN FEMALE BLOOD DONORS – RESULTS FROM THE DANISH BLOOD DONOR

STUDY

J. Dowsett

Copenhagen University Hospital, Copenhagen, Denmark

14:30 - 14:45 3C-S09-03 HIV-1 MOLECULAR EPIDEMIOLOGY AND PREVALENCE OF RESISTANCE ASSOCIATED MUTATIONS IN TREATMENT NAIVE BLOOD DONORS FROM CHINA

ELOOD DONORS FROM CF

J. Zhao

National Center for Clinical Laboratories, Beijing Hospital, National Center of Gerontology, Engineering Research Center of Laboratory Medicine, Graduate School, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China

14:45 - 15:00 3C-S09-04 BIOTINYLATION OF PLATELETS FOR TRANSFUSION PURPOSES-A NOVEL METHOD TO LABEL PLATELETS IN A CLOSED SYSTEM

S. de Bruin

Sanquin Research and Landsteiner Laboratory, Amsterdam, Netherlands, Amsterdam University Medical Centers, location AMC, Amsterdam, Netherlands

15:00 - 15:15 3C-S09-05 THE A1 INSULATOR REDUCES THE GENOTOXICITY OF A BETA-GLOBIN LENTIVIRAL VECTOR

G. Kaltsounis

George Papanicolaou Hospital, Thessaloniki, Greece

3C-S09-06

15:15 - 15:30 WEAK D ANTIGEN EXPRESSION COMMONLY RESULTS FROM SPLICING ALTERATION: CHARACTERIZATION OF NOVEL SPLICE SITE VARIANTS AND CORRELATION BETWEEN IN SILICO PREDICTIONS AND EXTENSIVE FUNCTIONAL STUDIES L. Raud

> UMR1078 Genetics, Functional Genomics and Biotechnology, Inserm, EFS, UBO, Brest, France, Laboratory of Excellence GR-Ex, Brest, France

14:00 - 15:30 Room: Shanghai

Donors and Donation - Blood Donor Retention & the Role of Side Effects

Moderators: J. Tiberghien (France) and L. Infanti (Switzerland)

14:00 - 14:30 INCENTIVES FOR BLOOD DONORS: DONOR RETURN RATE 3C-\$10-01 AMONG COMPENSATED AND NON-COMPENSATED BLOOD

DONORS M. Müller-Steinhardt

Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany, Red Cross Blood Servivce Baden-Württemberg - Hessen,

Mannheim, Germany

14:30 - 14:45
3C-S10-02
DEFERRAL AS THE POINT OF NO RETURN: A MIXED
METHODS APPROACH TO UNDERSTANDING WHOLE BLOOD
DONOR LAPSE AFTER TEMPORARY DEFERRAL

M. L. Spekman

Sanquin, Amsterdam, Netherlands, VU Amsterdam, Amsterdam, Netherlands

14:45 - 15:00 PREDICTION OF HEMOGLOBIN IN BLOOD DONORS USING A 3C-\$10-03 LATENT CLASS MIXED-FFFECTS TRANSITION MODE!

J van Rosmalen

Erasmus MC, Rotterdam, Netherlands

15:00 - 15:15 AN INTERVENTION STUDY FOR THE PREVENTION OF 3C-S10-04 VASOVAGAL REACTIONS: ANALYSIS OF DONORS' RETURN FOR

SUBSEQUENT DONATION

J. C. Wiersum

TRIP and Sanquin, Leiden, Netherlands

15:15 - 15:30 HEALTH STATUS, DONATION PATTERNS, AND IRON-DEFICIENCY 3C-S10-05 IN OLDER BLOOD DONORS- EVIDENCE FROM A LARGE

POPULATION-BASED COHORT AND HEALTH SERVICES USE DATA

S. Karki

Australian Red Cross Blood Service, Sydney, Australia

14:00 - 15:30 Room: Delhi



Transfusion Practitioner Session Anaemia management - The importance of the Transfusion Practitioner in the multidisciplinary team

Moderators: C. So-Osman (Netherlands) and J. Vanden Broeck (Belgium)

14:00 - 14:20 THE IMPORTANCE OF ANAEMIA MANAGEMENT AND IMPACT

3C-TP01-01 IN THE HEALTH CARE SETTING

<u>A. Mo</u>

Monash University, Melbourne, Australia, Monash Health, Clayton, Australia. Austin Health. Heidelberg. Australia

Australia, Austri Health, Heidelberg, Australia

14:20 - 15:00 ANAEMIA ASSESSMENT & MANAGEMENT: THE TP'S ROLE -

3C-TP01-02 PROCESSES, TIPS AND RESOURCES FOR CREATING CHANGE
L. Bielby & R. Moss

Victoria and Australian Red Cross Blood Service, Blood Matters,

West Melbourne, Australia

Great Ormond Street Hospital for Children NHS Foundation Trust,

London, United Kingdom

15:00 - 15:30 PANEL DISCUSSION

3C-TP01-03 L. Bielby, R. Moss, C. So-Osman, A. Mo

16:00 - 17:30

Plenary Room: San Francisco

Immunobiology - Red Blood Cell Destruction and Immune Regulation

Moderators: F. Pirenne (France) and S. Waldvogel (Switzerland)

16:00 - 16:30 INNATE IMMUNITY AND IMMUNE HAEMOLYTIC ANAEMIA

3D-S11-01 S.S. Zeerleder

Inselspital Bern, Bern, Switzerland

16:30 - 17:00 UNDERSTANDING ERYTHROCYTE CLEARANCE

3D-\$11-02 P. Buffet

Institut National de la Transfusion Sanguine, Paris, France

17:00 - 17:30 RED BLOOD CELLS AS MODULATORS OF INNATE IMMUNITY

3D-\$11-03 R. Riganò

Istituto Superiore di Sanità, Rome, Italy

16:00 - 17:30 Room: Montreal

Clinical - Haemoglobinopathies; State of the Art

Moderators: A. Al-Riyami (Oman) and M. Schmugge (Switzerland)

16:00 - 16:30 TRANSFUSION THERAPY IN SICKLE CELL DISEASE: WHICH

3D-S12-01 INDICATIONS AND FOR HOW LONG?

K. Yazdanbakhsh

New York Blood Center, New York, NY, United States

16:30 - 17:00 TREATMENT OF THALASSAEMIA

3D-S12-02 Y. Avdinok

Ege University, Faculty of Medicine, Bornova/Izmir, Turkey

17:00 - 17:15 SAFEGUARDING BLOOD SAFETY FOR PATIENTS WITH

3D-S12-03 THALASSAEMIA

C. Politis

Hellenic Centre for Disease Control and Prevention, Athens,

Greece

17:15 - 17:30 HEPCIDIN GENE POLYMORPHISMS AND IRON OVERLOAD
3D-\$12-04 IN MAJOR 6-THALASSEMIA PATIENTS REFRACTORY TO IRON

CHELATING THERAPY

P. Zarghamian

High Institute for Research and Education in Transfusion Medicine,

Tehran, Iran

16:00 - 17:30 Room: Sydney

Adverse Events - Update on Retroviruses in Transfusion Medicine

Moderators: M. Vermeulen (Netherlands) and H. Hirsch (Switzerland)

16:00 - 16:30 ENDING AIDS IN AFRICA - VISION OR ILLUSION?

3D-\$13-01 N. Labhardt

Swiss Tropical and Public Health Institute, Basel, Switzerland

16:30 - 16:45 EVOLVING BLOOD DONOR DEFERRAL POLICY FOR MEN WHO
3D-\$13-02 HAVE SEX WITH MEN IN FRANCE: IMPACT ON THE RISK OF

HIV TRANSMISSION BY TRANSFUSION

J. Pillonel

Santé publique France, Saint-Maurice, France

16:45 - 17:00 RISK FACTORS FOR RECENTLY ACQUIRED HIV INFECTION IN

3D-S13-03 BLOOD DONORS IN SOUTH AFRICA

K. van den Berg

South African National Blood Service, Port Elizabeth, South Africa,

University of Cape Town, Cape Town, South Africa

17:00 - 17:15 HIV-1 CLUSTERS AND RISK FACTORS IN BLOOD DONORS

3D-\$13-04 FOUND POSITIVE FOR HIV IN FRANCE

P. Cappy

INTS, Paris, France

17:15 - 17:30 FROM UNIVERSAL TO SELECTIVE HTLV SCREENING IN THE UK

3D-\$13-05 K. Davison

Public Health England, London, United Kingdom

16:00 - 17:30 Room: Boston

Management and Organisation -Improving Transfusion Organisation and Practice

Moderators: P. Flanagan (New Zealand) and A. Sarrai (Switzerland)

16:00 - 16:30 MANAGEMENT OF BLOOD SUPPLY IN A COUNTRY WITH LONG

3D-S14-01 DISTANCES M. Svriälä

Finnis Red Cross, Helsinki, Finland

16:30 - 16:45 FDUCATING THE MASSES: THE USE OF FLEARNING IN

3D-S14-02 TRANSFUSION MEDICINE

D. Peterson

BloodSafe eLearning Australia, North Adelaide, Australia

16:45 - 17:00 PROSPECTIVE PLATFLET AUDITING: ANALYSIS OF TRAINEF

3D-S14-03 COMPLIANCE WITH GUIDELINES

S. Vossoughi

Columbia University, New York, United States

WHAT CAN WE LEARN FROM HOW ADVERSE EVENTS ARE 17:00 - 17:15

3D-S14-04 DETECTED?

Ø. Flesland

Norwegian Directorate of Health, Oslo, Norway

17:15 - 17:30 HEMOGLOBIN MEASUREMENT - HOW TO EVALUATE NURSES' 3D-S14-05

COMPETENCE AND THE ACCURANCY OF THE POINT-OF-CARE

(POC) METHOD J. Castrén

Finnish Red Cross Blood Service, Helsinki, Finland

16:00 - 17:30 Room: Shanghai



Donors and Donation - Blood Donation; Iron Loss, Anemia and Beyond

Moderators: K. Magnussen (Denmark) and A. Holbro (Switzerland)

16:00 - 16:30

BLOOD DONATION AND IRON LOSS, WHAT ARE THE

3D-S15-01 IMPLICATIONS?

M.G.J. van Kraaij

Sanguin Blood Supply, Amsterdam, Netherlands

16:30 - 16:45 3D-S15-02 SUPERDONORS – GENETIC RISK PROFILE AND RISK OF LOW HEMOGLOBIN DEFERRAL

A. S. Rigas

University Hospital Copenhagen, Copenhagen, Denmark

16:45 - 17:00 3D-S15-03 MODELING OPTIMAL INTER-DONATION INTERVALS WITH PERSONALIZED RISK ASSESSMENT FOR ADVERSE IRON OUTCOMES

W. A. Russell

Stanford University, Stanford, United States, Vitalant Research

Institute, San Francisco, United States

17:00 - 17:15 3D-S15-04

A COMPOSITE MEASURE OF HEME IRON CONSUMPTION PREDICTS INCIDENT IRON DEPLETION IN REPEAT BLOOD

DONORS

B. R. Spencer

American Red Cross, Dedham, MA, United States

17:15 - 17:30 3D-S15-05 DIETARY INTAKE OF HEME IRON IS ASSOCIATED WITH FERRITIN AND HB LEVELS IN DUTCH BLOOD DONORS:

RESULTS FROM DONOR INSIGHT

K. van den Hurk

Sanguin Research, Amsterdam, Netherlands

Programme Tuesday, June

Programme at a Glance Tuesday, June 25



	San Francisco	Montreal	Sydney	Boston	Shanghai	Delhi	Kairo 2
08.30 - 10.00	4A-S16 What's New in Blood Cell Autoimmunity Anti-Ave Chiluk	44-S17 Patient Blood Management	44-S18 Current Relevance of Viruses, Parasities and Bacteria Infec- tions in Transfusion Medicine		4A-S19 Tools for Person- alleed Donor Care	Workshop on How to Improve Your Scientific Writing	
10.00 - 10.30			Visit t	Visit the Exhibition: Coffee Break	Break		
10.30 - 12.00	PL-02 Plenary Session Big Data						
12.00 - 14.00			Visit the Exhib	Visit the Exhibition, Lunch and Satellite Symposia	llite Symposia		
13.00 - 13.45						ISBT General Assembly	
14.00 - 15.30	4C-S20 Navel Blood Group Allekss	4C-S21 What's the matter with Platelet Function?	40-522 Severe Adverse Events other than TTID	4C-S23 Challenges in Resource Limited Settings	40-S24 Blood Component Collection - Effects on Donors and Recipients		Transfusion Practitioner Networking session
15.30 - 16.00			Visit t	Visit the Exhibition: Coffee Break	Break		
16.00 - 17.30	4D-S25 Platelet Alloimmunity		4D-S26 Evaluation of New Screening Platforms/ Assays	4D-S27 Reaching Out for More	4D-S28 Appoaches to Safe Donors		
17.30 - 18.30				Poster Session			
19.30 - 23.30		Congress P	arty (Markthalle, Base	 Tickets available at the 	Congress Party (Markthalle, Basel). Tickets available at the Registration Services desk (EUR 50)	sk (EUR 50)	

08:30 - 10:00 Room: Delhi

Workshop on How to Improve Your Scientific Writing

A highly interactive workshop that presents a reader-centered bottom line first approach to writing scientific papers. We will, among others, answer questions like: Who is going to read this, and why? Where do I begin? Can I use "me, myself and I"? Why are there so many referencing styles? Participants are encouraged to bring their own questions and please feel free to bring a paper that you're working on.

The workshop will be hosted by Bob van der Laaken.

Tuesday, June 25 08:30 - 10:00



Plenary Room: San Francisco

Immunobiology - What's New in Blood Cell Autoimmunity

Moderators: R. Petermann (France) and S.S. Zeerleder (Switzerland)

08:30 - 09:00 4A-S16-01 DETECTION OF PLATELET AUTOANTIBODIES TO IDENTIFY ITP

M. de Haas

Sanquin, Amsterdam, Netherlands, Sanquin, Leiden, Netherlands, LUMC, Leiden, Netherlands

09:00 - 09:15 4A-S16-02 THROMBOPOIETIN RECEPTOR AGONIST (TPO-RA) TREATMENT RAISES PLATELET COUNTS AND INDUCES IMMUNOMODULATION IN IMMUNE THROMBOCYTOPENIA (ITP).

J. W. Semple

Lund University, Lund, Sweden

09:15 - 09:30 4A-S16-03

AUTOANTIBODY MEDIATED CHANGES IN PLATELETS GLYCAN PATTERN: POTENTIAL IMPACT ON PLATELET FUNCTION AND LIFESPAN IN IMMUNE THROMBOCYTOPENIA

T. Bakchoul

Medical Faculty of Tübingen, Centre for Clinical Transfusion Medicine ZKT GmbH, Tübingen, Germany

09:30 - 09:45 4A-S16-04

AUTOIMMUNE HEMOLYTIC ANEMIA: SEROLOGICAL CHARACTERISTICS AND TRANSFUSION CHALLENGES

M. Raos

Clinical Hospital Centre Zagreb, Zagreb, Croatia

09:45 - 10:00 4A-S16-05 AUTOIMMUNE HAEMOLYTIC ANAEMIA: A SURVEY OF DIAGNOSTIC AND MANAGEMENT PRACTICE IN ENGLAND A. Charlton

NHS Blood and Transplant, Newcastle upon Tyne, United Kingdom

08:30 - 10:00 **Room: Montreal**

Clinical - Patient Blood Management

Moderators: E. Wood (Australia) and O. Theusinger (Switzerland)

08:30 - 09:00 AN UPDATE ON PATIENT BLOOD MANAGEMENT

4A-S17-01 K. Pavenski

St. Michael's Hospital, Toronto, Canada

09:00 - 09:15 LOW VS. HIGH HEMOGLOBIN TRIGGER FOR TRANSFLISION 4A-S17-02 IN VASCULAR SURGERY (TV): A RANDOMIZED CLINICAL

FFASIBILITY TRIAL (THE TV TRIAL)

A. Møller

Slagelse Hospital, Slagelse, Denmark

09:15 - 09:30 REDUCTION OF RED CELL UTILIZATION BY A HB-TRIGGERED

4A-S17-03 SINGLE-UNIT TRANSFUSION POLICY IN AN INPATIENT HEMATO-ONCOLOGICAL PATIENT POPULATION: A

RETROSPECTIVE SINGLE-CENTRE ANALYSIS

H. de Lil

Radboudumc, Nijmegen, Netherlands

09:30 - 09:45 ASSESSMENT OF HR CONTENT OF PACKED RED CELLS (PRBC).

4A-S17-04 IS IT TIME TO LABEL FACH UNIT WITH HB CONTENT?

R. Jain

AIIMS, New Delhi, India

09:45 - 10:00 EVALUATION OF CLINICAL PRACTICES OF RED BLOOD CELL 4A-S17-05

TRANSFUSIONS IN A TERTIARY CARE ONCOLOGY CENTRE

N. V. More

Tata Memorial Centre, Homi Bhabha National Institute, Mumbai,

India

08:30 - 10:00 Room: Sydney

Adverse Events - Current Relevance of Viruses, Parasites and Bacteria Infections in Transfusion Medicine

Moderators: D. Leiby (United States) and C. Tinguely (Switzerland)

08:30 - 09:00 APPROACHES TO CONTROL INFECTIONS IN VARIOUS

4A-S18-01 SETTINGS C. M. Neubling

Paul-Ehrlich-Institut, Langen, Germany

09:00 - 09:15 DETECTION OF BABESIA IN US BLOOD DONORS

4A-S18-02 L. Pate

Roche Molecular Systems, Pleasanton, United States

09:15 - 09:30 PREVALENCE OF BABESIA MICROTI IN CANADIAN BLOOD

4A-S18-03 DONORS S O'Brien

Canadian Blood Services, Ottawa, Canada

09:30 - 09:45 SEROEPIDEMIOLOGY OF TOXOPLASMA GONDII IN BLOOD DONORS IN PORTUGAL

A-S18-04 DONORS IN PORTUGAL F. Teixeira Rodrigues

University of Trás-os-Montes and Alto Douro (UTAD), Vila Real.

Portugal

09:45 - 10:00 WHO IS SYPHILIS TESTING EXCLUDING?

4A-S18-05 C. Reynolds

NHS Blood and Transplant, London, United Kingdom

08:30 - 10:00 Room: Shanghai

Donors and Donation - Tools for Personalised Donor Care

Moderators: M. Goldman (Canada) and S. Fontana (Switzerland)

08:30 - 09:00 CURRENT OPINION IN DONOR HEALTH - PERSONALISED

4A-S19-01 DONOR CARE

C. Erikstrup

Aarhus University Hospital, Aarhus, Denmark

PILOT OF DONOR ADVERSE EVENT SEVERITY GRADING TOOL 09:00 - 09:15

4A-S19-02 IN A LARGE BLOOD COLLECTION CENTER.

M. Townsend

Vitalant, Scottsdale, United States

09:15 - 09:30 COMPLICATIONS OF BLOOD DONATION: FLEVEN YEARS OF

4A-S19-03 INTERNATIONAL DATA

J. C. Wiersum

TRIP and Sanguin, Leiden, Netherlands

09:30 - 09:45 IMPLEMENTING FERRITIN TESTING IN STOCKHOLM - FIRST

4A-S19-04 **RFPORT**

M. K. Kvist

Karolinska University Hospital, Stockholm, Sweden

09:45 - 10:00 FERRITIN SCREENING IN THE NETHERLANDS: FIRST RESULTS 4A-S19-05

FROM A NATION WIDE DONOR DEFERRAL POLICY

M. Vinkenoog

Sanguin, Amsterdam, Netherlands

10:30 - 12:00

Plenary Room: San Francisco

Plenary Session: Big Data

Moderators: H. Ullum (Denmark) and S. Meyer (Switzerland)

10:30 - 11:00 THE 100,000 GENOMES PROJECT: HOW BIG DATA HELP
PATIENTS WITH RARE DISEASES (AND RARE BLOOD

GROUPS)
W. Ouwehand

University of Cambridge, Cambridge, United Kingdom

11:00 - 11:30 MOLECULAR GENETICS TO GENOMICS

PL-02-02 <u>F. Yamamoto</u>

Josep Carreras Leukaemia Research Institute (IJC), Badalona, Spain, Institut d'Investigació en Ciències de la Salut Germans Trias

i Pujol (IGTP), Badalona, Spain

11:30 - 12:00 METHODOLOGICAL CONSIDERATIONS FOR BIG DATA
PL-02-03 APPROACHES TO TRANSFUSION MEDICINE RESEARCH

N. Roubinian

Kaiser Permanente Division of Research, Oakland, United States, Vitalant Research Institute, San Francisco, United States, University of California, San Francisco, United States

12:00 - 14:00 Visit the Exhibition, Lunch and Satellite Symposia

14:00 - 15:30

Plenary Room: San Francisco

Immunobiology - Novel Blood Group Alleles

Moderators: C.F. van der Schoot (Netherlands) and S. Leion Crottet (Switzerland)

14:00 - 14:15 A LARGE DELETION SPANNING XG AND GYG2 CONSTITUTES A 4C-S20-01

GENETIC BASIS OF THE XGNILL PHENOTYPE, UNDERLYING

ANTI-Xga PRODUCTION

Y. Q. Lee

Lund University, Lund, Sweden

14:15 - 14:30 GYPB*S WITH TWO SILENCING CHANGES COMMONLY

4C-S20-02 INHERITED INDEPENDENTLY

J. E. Aeschlimann

NYBC, Long Island City, United States

14:30 - 14:45 A LUTHERAN RELATED ANTIBODY DETECTED IN A PATIENT 4C-S20-03 WITH A HOMOZYGOUS MISSENSE BCAM MUTATION

INDICATING A NOVEL ANTIGEN OF THE SYSTEM

I Muncher

Magen David Adom, Ramat-Gan, Israel

14:45 - 15:00 A NOVEL HIGH FREQUENCY ANTIGEN IN THE LUTHERAN

4C-S20-04 BLOOD GROUP SYSTEM (LUNU)

V. Karamatic Crew

NHS Blood and Transplant, Bristol, United Kingdom

15:00 - 15:15 CHARACTERIZATION OF A NOVEL HIGH-PREVALENCE ANTIGEN

IN THE JMH BLOOD GROUP SYSTEM

T. Peyrard

4C-S20-05

Institut National de la Transfusion Sanguine, Paris, France, UMR S1134 Inserm Université Paris Diderot, Paris, France, Laboratoire d'Excellence GR-Ex, Paris, France

15:15 - 15:30 B1.3GaINAc-T1-DEPENDENT EXTENSION OF THE HUMAN BLOOD GROUP B ANTIGEN RESULTS IN A NOVEL ABO-4C-S20-06 RELATED GLYCOLIPID STRUCTURE ON ERYTHROCYTES

J. Ricci Hagman

Lund University, Lund, Sweden, University Laboratories, Region Skåne, Lund, Sweden

14:00 - 15:30 Room: Montreal

Clinical - What's the matter with Platelet Function?

Moderators: J.J. Zwaginga (Netherlands) and G. Canellini (Switzerland)

14:00 - 14:30 AN UPDATE ON ANTI PLATELET AGENTS

4C-S21-01 D. Cox

Royal College of Surgeons in Ireland, Dublin, Ireland

14:30 - 15:00 PLATELET FUNCTION MEASUREMENTS IN TRANSFUSION

4C-S21-02 MEDICINE P. Fontana

University Hospitals of Geneva, Geneva, Switzerland

15:00 - 15:15 PLATELET COMPATIBILITY AND PLATELET ANTIBODIES

4C-S21-03 DETECTION: A STEP TOWARDS RESOLVING DILEMMA IN MANAGEMENT OF PLATFLET REFRACTORINESS IN ONCOLOGY

PATIENTS S. Mangwana

Sri Balaii Action Medical Institute, New Delhi, India

15:15 - 15:30 ASSESSMENT OF CORRELATION OF PLATELET CROSSMATCH
4C-\$21-04 RESULTS BY SOLID PHASE RED CELL ADHERENCE ASSAY

RESULTS BY SOLID PHASE RED CELL ADHERENCE ASSAY (SPRCA) WITH POST-TRANSFUSION PLATELET COUNT INCREMENT IN ADULT HEMATO-ONCOLOGY PATIENTS

P. B. Sontakke

Tata Memorial Centre, Mumbai, India



14:00 - 15:30 Room: Sydney

Adverse Events - Severe Adverse Events other than TTID

Moderators: Y.L. Fung (Australia) and R. Henschler (Germany)

14:00 - 14:30 UPDATE ON TRALI/TACO AND TAD (AABB PRE MEETING)

4C-S22-01 A. Vlaar

Amsterdam UMC, Amsterdam, Netherlands

14:30 - 15:00 IRON OVERLOAD FROM TRANSFUSION AND IMPACT ON

4C-S22-02 TRANSPLANT OUTCOMES

E. Angelucci

IRCCS Ospedale Policlinico San Martino, Genova, Italy

15:00 - 15:30 IMPACT OF BLOOD DONOR SEX ON RECIPIENT OUTCOMES

4C-S22-03 R. A. Middelburg

Sanquin Research, Leiden, Netherlands, Leiden University Medical

Center, Leiden, Netherlands

14:00 - 15:30 Room: Boston

Management and Organisation - Challenges in Resource Limited Settings

Moderators: R. Reddy (South Africa) and D. Castelli (Switzerland)

14:00 - 14:30 CHALLENGES OF BLOOD COMPONENT THERAPY IN SUB-

4C-S23-01 SAHARA AFRICA

J. Mulenga

Zambia National Blood Transfusion Service, lusaka, Zambia

14.30 - 15.00 CHALLENGES OF CLINICAL TRIALS IN RESOURCE LIMITED

4C-S23-02 **SETTINGS**

A. Kambugu

Infectious Diseases Institute, Makerere University, Kampala,

Uganda

15:00 - 15:30 TOWARD AN APPROPRIATE PATHOGEN REDUCTION 4C-S23-03

TECHNOLOGY FOR WHOLE BLOOD IN RESOURCE-LIMITED.

SETTINGS S. Amar

Transfusion CRS Suisse, Bern, Switzerland

14:00 - 15:30 Room: Kairo 2

The Transfusion Practitioner networking session

The Transfusion Practitioner (TP) networking session and is a perfect opportunity for TPs to meet and connect with transfusion colleagues, network and discuss common interests within the field of international transfusion.

14:00 - 15:30 Room: Shanghai

Donors and Donation - Blood Component Collection - Effects on Donors and Recipients

Moderators: E. McSweeney (Ireland) and H. Andreu-Ullrich (Switzerland)

14:00 - 14:18 BRINGING FIRST-TIME PLASMA DONORS BACK: FINDINGS OF 4C-\$24-01 AN INTERVENTION STUDY

T.E. Davison

Australian Red Cross Blood Service, Melbourne, Australia

14:18 - 14:36 DOUBLE-ERYTHROCYTE APHERESIS VERSUS CONVENTIONAL WHOLE BLOOD PHI FROTOMY AS IRON DEPLETION

TREATMENT IN HEALTHY CARRIERS OF HEE MUTATIONS WITH

HYPERFERRITINEMIA

L. Infanti

Blood Donation Center Swiss Red Cross Basel, Switzerland, University Hospital, Basel, Switzerland

14:36 - 14:54 LONG- TERM COURSE OF HEMOGLOBIN AND FERRITIN

4C-S24-03 VALUES IN HIGH-FREQUENCY BLOOD DONORS DONATING WHOLE BLOOD OR DOUBLE FRYTHROCYTE APHERESIS

V. Pehlic

Blood Donation Centre Basel, Switzerland

14:54 - 15:12 IMPACT OF HYDROXYETHYL STARCH AND MODIFIED FLUID
4C-\$24-04 GELATIN ON GRANULOCYTE PHENOTYPE AND FUNCTION

N. Doblinger

University Hospital Regensburg, Regensburg, Germany

15:12 - 15:30 PLATELETPHERESIS DONATIONS AND DONOR RISK OF 4C-\$24-05 SUSTAINED THROMBOPENIA

J.-Y. Py

EFS Centre Pays de la Loire, Saint Jean de la Ruelle, France

16:00 - 17:30

Plenary Room: San Francisco

Immunobiology - Platelet Alloimmunity

Moderators: E. Muniz-Diaz (Spain) and I. Hegemann (Switzerland)

16:00 - 16:30 HLA IN BLOOD TRANSFUSION

4D-\$25-01 Z. Grubic

4D-S25-02

University Hospital Centre Zagreb, Zagreb, Croatia

16:30 - 16:45 SURFACE PLASMON RESONANCE-BASED DETECTION OF

ANTI-HPA 1A ANTIBODY GLYCOSYLATION, AN ASSAY TO PREDICT DISEASE SEVERITY IN ALLOIMMUNE CYTOPENIAS

Z. Szittner

Sanquin Research, and Landsteiner Laboratory, Amsterdam,

Netherlands

16:45 - 17:00 RESULTS OF HPA-1A SCREENING PROGRAM FOR

4D-S25-03 IDENTIFICATION OF PREGNANT WOMEN AT RISK OF FOETAL/

NEONATAL ALLOIMMUNE THROMBOCYTOPENIA (FNAIT)

E. Brojer

Institute of Hematology and Transfusion Medicine, Warsaw, Poland

17:00 - 17:15 PLATELET ALLOIMMUNIZATION AND CLINICAL

4D-S25-04 MANIFESTATIONS IN THE MATERNO-FOETAL CONTEXT

R. Petermann

Centre de Recherche des Cordeliers, INSERM, USPC, Université

Paris Descartes, Université Paris, Paris, France

17:15 - 17:30 FAST AND LOW-COST MATERNAL HPA-1A TYPING ELISA FOR HIGH-THROUGHPUT SCREENING OF WOMEN AT RISK FOR

FNAIT

C.E. van der Schoot

Sanquin, Amsterdam, Netherlands

17:30 - 18:30 Poster Session

16:00 - 17:30 Room: Sydney

Adverse Events - Evaluation of New Screening Platforms/Assays

Moderators: B. Custer (United States) and H. Hirsch (Switzerland)

16:00 - 16:15 EVALUATING AN AUTOMATED CMV SCREENING ASSAY AT THE

4D-\$26-01 IBTS- A CHALLENGING PROCESS FOR BLOOD SCREENING

LABORATORIES D. Covne

Irish Blood Transfusion Service, Dublin, Ireland

mon blood nanolasion corvice, babini, nolane

16:15 - 16:30 DRIED PLASMA SPOT TESTING – THE ANSWER FOR MAKING 4D-\$26-02 BLOOD TRANSFUSION TESTING SAFER IN AFRICA?

C Pistorius

Western Cape Blood Service, Cape Town, South Africa

16:30 - 16:45 EXPERIENCE WITH THE ALINITY S ASSAYS AFTER 5 MONTHS

4D-S26-03 OF ROUTINE USE IN HGH-VOLUME BLOOD DONATION

SCREENING A. van Weert

Sanquin Bloodsupply, Amsterdam, Netherlands

16:45 - 17:00 EVALUATION OF THE USABILITY OF THE NEWLY LAUNCHED
4D-\$26-04 ALINITY S AND THE SPECIFICITY OF HIV COMBO. ANTI-HCV.

ALINITY S AND THE SPECIFICITY OF HIV COMBO, ANTI-HCV, HBSAG AND SYPHILIS IN A BLOOD DONOR SCREENING SETTING

C. Tinguely
Interregionale Blutspende SRK AG. Bern. Switzerland

interregionale blutspende SKK AG, Berri, Switzerland

4D-S26-05 INFECTIOUS DISEASE PARAMETERS ON THE COBAS E 801

ANALYSER FOR ROUTINE FIRST-TIME BLOOD DONOR SCREENING

EVALUATING THE CLINICAL PERFORMANCE OF FLECSYS®

F. Langen

Roche Diagnostics GmbH, Penzberg, Germany

17:15 - 17:30 SIDE BY SIDE COMPARISON OF SPECIFICITY OF ALINITY S AND

4D-\$26-06 COBAS E801 SEROLOGICAL ASSAYS IN SERUM AND PLASMA SAMPLES

E. M. Wagner

Takeda, Vienna, Austria

17:30 - 18:30 Poster Session

17:00 - 17:15

Tuesday, June 25

16:00 - 17:30 Room: Boston

Cellular Therapies - Reaching Out for More

Moderators: E. Seifried (Germany) and J. Passweg (Switzerland)

16:00 - 16:30 TUMOUR SPECIFIC CELLULAR THERAPIES

4D-\$27-01 H. Läubli

University of Basel, Basel, Switzerland

16:30 - 17:00 CELLULAR THERAPIES IN THE AGE OF CRISPR-CAS

4D-S27-02 T. Cathomen

Medical Center - University of Freiburg, Freiburg, Germany

17:00 - 17:30 T CELL CELLULAR THERAPIES

4D-S27-03 M.C. Wolkers

Sanguin Research, Amsterdam, Netherlands

17:30 - 18:30 Poster Session

Tuesday, June 25

16:00 - 17:30 Room: Shanghai

Donors and Donation - Appoaches to Safe Donors

Moderators: J. Castrén (Finland) and T. Weingand (Switzerland)

16:00 - 16:30 MOVING TOWARDS VOLUNTARY NON-REMUNERATED BLOOD

4D-\$28-01 DONATION IN THE BALTIC STATES: A COMMON STARTING
POINT DOES NOT GUARANTEE THE SAME RESULTS

R. Kullaste

R. Kullaste

North Estonia Medical Centre's Blood Centre, Tallinn, Estonia

16:30 - 16:50 DEMOGRAPHIC AND HEMATOLOGICAL PARAMETERS IN FIRST

4D-\$28-02 TIME BLOOD DONORS S. 7vkova

Innlandet Hospital Trust, Lillehammer, Norway, UiT-The Arctic

University of Norway, Tromsoe, Norway

16:50 - 17:10 POST-DONATION INFORMATION MANAGAMENT - CONTRIBU
4D-\$28-04 TION TO THE SAFETY OF TRANSFLISION TREATMENT

T. Vuk

Croatian Institute of Transfusion Medicine, Zagreb, Croatia

17:10 - 17:30 THE DEXTOR PROJECT: DATA EXCHANGE IN TRANSFUSION, 4D-S28-05 OPEN RESOURCE

B. I. Whitaker

U.S. Food & Drug Administration, Silver Spring, MD, United States

17:30 - 18:30 Poster Session

Programme Wednesday, June 2

Programme at a Glance Wednesday, June 26

	San Francisco	Montreal	Sydney	Singapore	Samarkand
08.30 - 10.00 5A-\$29	5A-S29 Red Cell Alloimmunity	5A-S30 Haemovigilance	5A-S31 New Indications for Pathogen Reduction Methods	5A.S32 Donor Adherence - are we doing the right fring?	Pitch your research idea Participan's present their research idea to a panel of experts and receive feedback
10.00 - 10.30			Coffee Break		
10.30 - 12.00 Plenary A Glimp	PL-03 Plenary Session A Glimpse of the Future				
12.00 - 12.15	Closing Ceremony				
12.15 - 13.30			Farewell Lunch		

Plenary Session

■ Blood Products
■ Clinical
■ Cellular Therapies
■ Donors / Donation
■ Adverse events
■ Immunobiology of Blood Cells
■ Management & Organization
□ Other Sessions

Wednesday, June 26 08:30 - 10:00 Room: Samarkand

Present your research idea to a panel of experts

The workshop will be hosted by Henrik Ullum and a small panel of experts. Attendees, who registered and were selected will have the possibility to present their research ideas to the panel in 5 minutes. After the presentation, the expert panel will give tips and suggestions.

08:30 - 10:00

Plenary Room: San Francisco

Immunobiology - Red Cell Alloimmunity

Moderators: G. Clarke (Canada) and H. Hustinx (Switzerland)

08:30 - 09:00 RECIPIENT FACTORS INFILIENCING RED BLOOD CELL

5A-S29-01 ALLOIMMUNIZATION

J. Hendrickson

Yale University, New Haven, United States

09:00 - 09:15 FREQUENCY OF RED CELL ALLOIMMUNISATION IN PATIENTS.

5A-S29-02 WITH SICKLE CELL DISEASE IN OMAN

H. Al Balushi

Royal Hospital, Muscat, Oman

RED BLOOD CELL ANTIBODIES IN MULTI-TRANSFUSED. 09:15 - 09:30

5A-S29-03 PATIENTS WITH SICKLE CELL DISEASE IN GHANA: PREVALENCE. SPECIFICITIES AND RISK FACTORS

L. A. Boateng

Liverpool School of Tropical medicine, Liverpool, United Kingdom. Sanguin, Amsterdam, Netherlands, Kwame Nkrumah University of

Science and Technology, Kumasi, Ghana

09:30 - 09:45 STRONG PREGNANCY INDUCED ANTI-D IMMUNIZATION IN 5A-S29-04

DEL PHENOTYPE WITH RHD*01EL.04 ALLELE

M. Pisacka

Institute of Haematology and Blood Transfusion, Prague, Czech

Republic

09:45 - 10:00 ANTI-RBA IS A VERY FREQUENT RED CELL ANTIBODY IN

5A-S29-05 **GERMANY**

E. A. Scharberg

Institute for Transfusion Medicine and Immunohematology. DRK-BSD Ba-Wü-He, Baden-Baden, Germany

10:00 - 10:30 Coffee Break

08:30 - 10:00 **Room: Montreal**

Clinical - Haemovigilance

Moderators: K. Land (United States) and M. Jutzi (Switzerland)

THE IMPORTANCE AND THE APPROACH TO SET UP A SYSTEM 08:30 - 09:00 5A-S30-01 OF HEMOVIGILANCE

T. Aung

Ministry of Health and Sports, Yangon, Myanmar

09:00 - 09:15 LEARNING FROM TRANSFUSION 'NEVER EVENTS' - REVIEW OF 5A-S30-02 UNINTENTIONAL ABO INCOMPATIBLE TRANSFUSIONS AS

REPORTED TO SERIOUS HAZARDS OF TRANSFUSION 2010-

2017

S. Naravan

Serious Hazards of Transfusion, Manchester, United Kingdom

09:15 - 09:30 HEMOVIGII ANCE ON MIRASOL PATHOGEN-REDUCED WHOLE 5A-S30-03

BLOOD IN GHANA

S. Owusu-Ofori

Komfo Anokye Teaching Hospital, Kumasi, Ghana

09:30 - 09:45 IRRADIATED BLOOD PRODUCT USE IN PATIENTS AT RISK FOR 5A-S30-04 TRANSFUSION-ASSOCIATED GRAFT-VERSUS-HOST DISEASE

H. L. A. Yuen

Monash Health, Melbourne, Australia

09:45 - 10:00 TRANSFUSION RELATED ADVERSE EVENT REPORTING AND 5A-S30-05

DOCUMENTATION COMPLIANCE AMONG HEALTHCARE PROFESSIONALS IN DEVELOPING COUNTRY- AIMING

TOWARDS IMPROVING PRACTICES

N. Anwar

National Institute of Blood Diseases and Bone Marrow Transplant.

Karachi, Pakistan

10:00 - 10:30 Coffee Break

08:30 - 10:00 Room: Sydney

Adverse Events - New Indications for Pathogen Reduction Methods

Moderators: S. Ramirez-Arcos (Canada) and M. Prudent (Switzerland)

08:30 - 09:00 IMPACT OF PATHOGEN INACTIVATION ON PLATELET SURVIVAL

5A-S31-01 AND ALLOIMMUNIZATION

A. S. Buser

Regional Blood Transfusion Service, Swiss Red Cross, Basel,

Switzerland

09:00 - 09:15 EFFICIENT INACTIVATION OF BRUCELLA CLINICAL ISOLATES IN 54-531-02 HUMAN PLATFLET CONCENTRATES IN 100% PLASMA WITH

HUMAN PLATELET CONCENTRATES IN 100% PLASMA WITH AMOTOSALEN AND ULTRAVIOLET A LIGHT TREATMENT

F. Alseraye

Security Forces Hospital, Riyadh, Saudi Arabia

09:15 - 09:30 THERAPEUTIC RESPONSE TO AMOTOSALEN/UVA-TREATED
5A-S31-03 PLATFLETS WITH UP TO 7 DAYS STORAGE DURING 5 YEARS

OF ROUTINE PRACTICE

L. Infanti

Swiss Red Cross, Division of Hematology, University Hospital,

Basel, Switzerland

09:30 - 09:45 NIPAHVIRUS IS EFFICIENTLY INACTIVATED IN PLATELET

5A-S31-04 CONCENTRATES BY UVC LIGHT USING THE THERAFLEX UV

PLATELETS TECHNOLOGY

W. Handke

Red Cross Blood Service NSTOB, Springe, Germany

09:45 - 10:00 USE OF PLATELET PATHOGEN REDUCTION TO IMPROVE STOCK
5A-S31-05 MANAGEMENT IN A NATIONAL BLOOD SERVICE

N. Arnason

Landspitali-The National University Hospital of Iceland, Reykjavik University, Iceland

10:00 - 10:30 Coffee Break

08:30 - 10:00 Room: Singapore

Donors and Donation - Donor Adherence - are we doing the Right Thing?

Moderators: P. van den Burg (Netherlands) and G. Nicoloso (Switzerland)

08:30 - 09:00 KEEPING THE BLOOD FLOWING

5A-S32-01 L. Eberhart

Austrian Red Cross, Wien, Austria

09:00 - 09:15 THE BEHAVIOURAL CHARACTERISTICS OF FIRST-TIME BLOOD
5A-\$32-02 DONORS IN TURKEY: AN EXTENSIVE ANALYSIS OF THEORY OF

PLANNED BEHAVIOUR MODEL

N. N. Sozmen

Turkish Red Crescent, Ankara, Turkey

09:15 - 09:30 TOWARDS MORE UNIFORM DONOR ELIGIBILITY CRITERIA:

5A-S32-03 OVERVIEW OF FIRST RESULTS FROM TRANSPOSE

M.G.J. van Kraaij

Sanquin, Amsterdam, Netherlands

09:30 - 09:45 CURRENT PRACTICES IN DONOR SELECTION AND PROTECTION ACROSS EUROPEAN COUNTRIFS AND

SUGGESTIONS FOR IMPROVEMENT – THE CASE OF BLOOD

AND PLASMA E.-M. Merz

Sanquin Blood Supply, Amsterdam, Netherlands

09:45 - 10:00 LARGE DIFFERENCES IN THE REPORTING OF ADVERSE

REACTIONS IN BLOOD AND PLASMA DONATION WITHIN

THE EUROPEAN UNION - RESULTS FROM THE TRANSPOSE

PROJECT C. Mikkelsen

Copenhagen University Hospital, Copenhagen, Denmark

10:00 - 10:30 Coffee Break

5A-S32-05

10:30 - 12:00

Plenary Room: San Francisco

Plenary Session: A Glimpse of the Future

Moderators: M.L. Olsson (Sweden) and B. Mansouri (Switzerland)

10:30 - 11:00 INVISIBLE ORGANS

PL-03-01 R. Blasczyk

Hannover Medical School, Hannover, Germany

11:00 - 11:30 GENE EDITING IN SICKLE CELL DISEASE

PL-03-02 D. Bauer

Boston Children's Hospital, Boston, United States

11:30 - 12:00 THE WATT WORMS - TAKE A DEEP BREATH

PL-03-03 F. Zal

Hemarina SA, Morlaix, France

12:00 - 12:15 Closing Ceremony

12:15 - 13:30 Farewell Lunch

Speakers Index

Aeschlimann Agrawal Ahlen Al Balushi Alseraye Altwegg Amar Angelucci Anwar Armason Aung Ausset Aydinok Bakchoul Baron Bauer Bayat Berti Bielby Blasczyk Bloch Boateng Brassel Brojer Buffet Busch Buser Candotti Cappy Castrén Cathomen Charlton Clausen Cox Coyne Crighton Custer Davison	J.E. S. M.T. H. F. K. S. E. N.N. T. S. Y. T. D. D. B. P. L. A. E. P. M. S. D. D. G. B. E. T. A. F. B. D. D. G. F. E. A. E. P. M. S. D. P. J. T. A. F. B. D. D. G. B. F. E. T. C. D. D. G. B. F. E. T. T. A. F. B. D. D. G. B. T. E. T.	4C-S20-02 3A-S01-01 2D-08-02 5A-S29-02 5A-S31-02 1D-04-01 4C-S23-03 4C-S22-02 5A-S30-05 5A-S31-05 5A-S30-01 1B-02-03 3D-S12-02 4A-S16-03 PL-03-02 2D-08-03 3C-S07-03 3A-S01-03 PL-03-01 2C-05-01 5A-S29-03 3C-S08-03 4D-S25-03 3D-S11-02 3A-S03-05 5A-S31-01 3C-S08-02 4A-S16-05 2C-06-03 4C-S21-01 4D-S26-01 2B-04-03 3A-S03-03 2A-01-02	3C-TP01-02
Davison	I.E.	2A-01-02	4C-S24-01
Davison	K.	3D-S13-05	

de Bruin	S.	3C-S09-04	
de Haas	M.	4A-S16-01	
de Lil	H.	4A-S17-03	
Doblinger	N.	4C-S24-04	
Dowsett	J.	3C-S09-02	
Eberhart	L.	5A-S32-01	
Erikstrup	C.	4A-S19-01	
Ferrand	C.	1B-02-02	
Figueiredo	C.	1C-03-03	
Flanagan	P.	2B-03-02	
Flesch	B.K.	2D-08-01	
Flesland	Ø.	3D-S14-04	
Floch	Α.	3A-S02-03	
Folman	C.	2A-02-02	
Fontana	P.	4C-S21-02	
Fournier-Wirth	C.	3A-S03-02	
Gabriel	C.	1A-01-01	
Garzon Jimenez	R.C.	3A-S03-04	
Gassner	C.	3A-S02-02	
Gatare	S.	2D-07-02	
Gauvin	F.	2B-04-02	
Geerts	В.	2B-03-01	
Gleadall	N.	3C-S06-03	
Greinacher	Α.	PL-01-03	
Grubic	7.	4D-S25-01	
Gupta	Α.	3C-S07-05	
Handke	W.	5A-S31-04	
Helge	J.W.	2A-01-01	
Hellberg	Å.	2C-06-01	
Hendrickson	J.	5A-S29-01	
Hirsch	Н.	3C-S08-01	
Holzhauer	S.	3C-S07-01	
Hurst Majno	S.	PL-01-02	
Ilbars	T.	3A-S05-02	
Indermuehle	L.	3A-S05-01	
Infanti	L.	4C-S24-02	5A-S31-03
Jain	R.	4A-S17-04	
Javed	R.	3C-S06-05	
Jeker	L.	1D-04-02	

Jensen H.G. 2D-07-01 Kaltsounis G. 3C-809-05 Kambugu A. 4C-S23-02 Karis T. 3A-S04-03 Karamatic Crew V. 4C-S20-04 Karki S. 3C-S10-05 Kullaste R. 4D-S28-01 Kumukova I. 3C-S07-04 Kutac D. 3A-S01-06 Kvist M.K. 4A-S19-04 Labhardt N. 3D-S13-01 Lane W. 3A-S02-04 Lane W. 3A-S02-04 Langen F. 4D-S26-05 Langi Sasongko P. 3C-S09-01 Larsson L. 3A-S04-04 Labli H. 4D-S27-01 Lee Y.Q. 4C-S20-01 Lima Pinto B. 3A-S01-05 Lodge L. 2D-07-03 Lorgiore E. 2B-04-01 Lozano M. 2C-05-03 Merz <t< th=""><th></th><th></th><th></th></t<>			
Kambugu A. 4C-S23-02 Kanias T. 3A-S04-03 Karamatic Crew V. 4C-S20-04 Karki S. 3C-S10-05 Kullaste R. 4D-S28-01 Kumukova I. 3C-S07-04 Kutac D. 3A-S01-06 Kvist M.K. 4A-S19-04 Labhardt N. 3D-S13-01 Lane W. 3A-S02-04 Langen F. 4D-S26-05 Langi Sasongko P. 3C-S09-01 Larsson L. 3A-S04-04 Läubli H. 4D-S27-01 Lee Y.Q. 4C-S20-01 Lima Pinto B. 3A-S01-05 Lodge L. 2D-07-03 Lopriore E. 2B-04-01 Lozano M. 2C-05-03 Maitland K. PL-01-01 Mangwana S. 4C-S21-03 Merz EM. 5A-S32-04 Middelburg	Jensen	H.G.	2D-07-01
Kanias T. 3A-S04-03 Karamatic Crew V. 4C-S20-04 Karki S. 3C-S10-05 Kullaste R. 4D-S28-01 Kumukova I. 3C-S07-04 Kutac D. 3A-S01-06 Kvist M.K. 4A-S19-04 Labhardt N. 3D-S13-01 Lane W. 3A-S02-04 Langen F. 4D-S26-05 Langi Sasongko P. 3C-S09-01 Larsson L. 3A-S04-04 Läubli H. 4D-S27-01 Lee Y.Q. 4C-S20-01 Lima Pinto B. 3A-S01-05 Lodge L. 2D-07-03 Lopriore E. 2B-04-01 Lozano M. 2C-05-03 Maitland K. PL-01-01 Mangwana S. 4C-S21-03 Merz EM. 5A-S32-04 Middelburg R.A. 4C-S22-03 Mikkelsen <td>Kaltsounis</td> <td>G.</td> <td>3C-S09-05</td>	Kaltsounis	G.	3C-S09-05
Karamatic Crew V. 4C-S20-04 Karki S. 3C-S10-05 Kullaste R. 4D-S28-01 Kumukova I. 3C-S07-04 Kutac D. 3A-S01-06 Kvist M.K. 4A-S19-04 Labhardt N. 3D-S13-01 Lane W. 3A-S02-04 Langen F. 4D-S26-05 Langi Sasongko P. 3C-S09-01 Larsson L. 3A-S04-04 Läubli H. 4D-S27-01 Lee Y.Q. 4C-S20-01 Lima Pinto B. 3A-S01-05 Lodge L. 2D-07-03 Lopriore E. 2B-04-01 Lozano M. 2C-05-03 Maitland K. PL-01-01 Mangwana S. 4C-S21-03 Merz EM. 5A-S32-04 Middelburg R.A. 4C-S22-03 Mikkelsen C. 5A-S32-05 Mo	Kambugu	A.	4C-S23-02
Karki S. 3C-S10-05 Kullaste R. 4D-S28-01 Kumukova I. 3C-S07-04 Kutac D. 3A-S01-06 Kvist M.K. 4A-S19-04 Labhardt N. 3D-S13-01 Lane W. 3A-S02-04 Langen F. 4D-S26-05 Langi Sasongko P. 3C-S09-01 Larsson L. 3A-S04-04 Läubli H. 4D-S27-01 Lee Y.Q. 4C-S20-01 Lima Pinto B. 3A-S01-05 Lodge L. 2D-07-03 Lopriore E. 2B-04-01 Lozano M. 2C-05-03 Maitland K. PL-01-01 Mangwana S. 4C-S21-03 Mikkelsen C. 5A-S32-04 Middelburg R.A. 4C-S22-03 Mikkelsen C. 5A-S32-05 Mo A. 3C-TP01-01 More	Kanias	T.	3A-S04-03
Kullaste R. 4D-S28-01 Kumukova I. 3C-S07-04 Kutac D. 3A-S01-06 Kvist M.K. 4A-S19-04 Labhardt N. 3D-S13-01 Lane W. 3A-S02-04 Langen F. 4D-S26-05 Langi Sasongko P. 3C-S09-01 Larsson L. 3A-S04-04 Läubli H. 4D-S27-01 Lee Y.Q. 4C-S20-01 Lima Pinto B. 3A-S01-05 Lodge L. 2D-07-03 Lopriore E. 2B-04-01 Lozano M. 2C-05-03 Maitland K. PL-01-01 Mangwana S. 5A-S32-04 Middelburg R.A. 4C-S21-03 Mikkelsen C. 5A-S32-05 Mo A. 3C-TP01-01 Moller A. 4A-S17-02 More N.V. 4A-S17-05 Moss <t< td=""><td>Karamatic Crew</td><td>V.</td><td>4C-S20-04</td></t<>	Karamatic Crew	V.	4C-S20-04
Kullaste R. 4D-S28-01 Kumukova I. 3C-S07-04 Kutac D. 3A-S01-06 Kvist M.K. 4A-S19-04 Labhardt N. 3D-S13-01 Lane W. 3A-S02-04 Langen F. 4D-S26-05 Langi Sasongko P. 3C-S09-01 Larsson L. 3A-S04-04 Läubli H. 4D-S27-01 Lee Y.Q. 4C-S20-01 Lima Pinto B. 3A-S01-05 Lodge L. 2D-07-03 Lopriore E. 2B-04-01 Lozano M. 2C-05-03 Maitland K. PL-01-01 Mangwana S. 5A-S32-04 Middelburg R.A. 4C-S21-03 Mikkelsen C. 5A-S32-05 Mo A. 3C-TP01-01 Moller A. 4A-S17-02 More N.V. 4A-S17-05 Moss <t< td=""><td>Karki</td><td>S.</td><td>3C-S10-05</td></t<>	Karki	S.	3C-S10-05
Kutac D. 3A-S01-06 Kvist M.K. 4A-S19-04 Labhardt N. 3D-S13-01 Lane W. 3A-S02-04 Langen F. 4D-S26-05 Langi Sasongko P. 3C-S09-01 Larsson L. 3A-S04-04 Läubli H. 4D-S27-01 Lee Y.Q. 4C-S20-01 Lima Pinto B. 3A-S01-05 Lodge L. 2D-07-03 Lorjoriore E. 2B-04-01 Lozano M. 2C-05-03 Maitland K. PL-01-01 Mangwana S. 4C-S21-03 Merz EM. 5A-S32-04 Middelburg R.A. 4C-S22-03 Mikkelsen C. 5A-S32-05 Mo A. 3C-TP01-01 Møller A. 4S-17-05 Moss R. 3C-TP01-02 Mulenga J. 4C-S23-01 Müller-Steinhardt	Kullaste	R.	4D-S28-01
Kutac D. 3A-S01-06 Kvist M.K. 4A-S19-04 Labhardt N. 3D-S13-01 Lane W. 3A-S02-04 Langen F. 4D-S26-05 Langi Sasongko P. 3C-S09-01 Larsson L. 3A-S04-04 Läubli H. 4D-S27-01 Lee Y.Q. 4C-S20-01 Lima Pinto B. 3A-S01-05 Lodge L. 2D-07-03 Lorjoriore E. 2B-04-01 Lozano M. 2C-05-03 Maitland K. PL-01-01 Mangwana S. 4C-S21-03 Merz EM. 5A-S32-04 Middelburg R.A. 4C-S22-03 Mikkelsen C. 5A-S32-05 Mo A. 3C-TP01-01 Møller A. 4S-17-05 Moss R. 3C-TP01-02 Mulenga J. 4C-S23-01 Müller-Steinhardt	Kumukova	1.	3C-S07-04
Kvist M.K. 4A-S19-04 Labhardt N. 3D-S13-01 Lane W. 3A-S02-04 Langen F. 4D-S26-05 Langi Sasongko P. 3C-S09-01 Larsson L. 3A-S04-04 Läubli H. 4D-S27-01 Lee Y.Q. 4C-S20-01 Lima Pinto B. 3A-S01-05 Lodge L. 2D-07-03 Lopriore E. 2B-04-01 Lozano M. 2C-05-03 Maitland K. PL-01-01 Mangwana S. 4C-S21-03 Merz EM. 5A-S32-04 Middelburg R.A. 4C-S21-03 Mikkelsen C. 5A-S32-05 Mo A. 3C-TP01-01 Møller A. 4A-S17-02 More N.V. 4A-S17-05 Moss R. 3C-TP01-02 Mulenga J. 4C-S23-01 Müller-Steinhardt			
Labhardt N. 3D-S13-01 Lane W. 3A-S02-04 Langen F. 4D-S26-05 Langi Sasongko P. 3C-S09-01 Larsson L. 3A-S04-04 Läubli H. 4D-S27-01 Lee Y.Q. 4C-S20-01 Lima Pinto B. 3A-S01-05 Lodge L. 2D-07-03 Lopriore E. 2B-04-01 Lozano M. 2C-05-03 Maitland K. PL-01-01 Mangwana S. 4C-S21-03 Merz EM. 5A-S32-04 Middelburg R.A. 4C-S21-03 Mikkelsen C. 5A-S32-05 Mo A. 3C-TP01-01 Møller A. 4A-S17-02 More N.V. 4A-S17-05 Moss R. 3C-TP01-01 Mulenga J. 4C-S23-01 Müller-Steinhardt M. 3C-S10-01 Muncher			
Lane W. 3A-S02-04 Langen F. 4D-S26-05 Langi Sasongko P. 3C-S09-01 Larsson L. 3A-S04-04 Läubli H. 4D-S27-01 Lee Y.Q. 4C-S20-01 Lima Pinto B. 3A-S01-05 Lodge L. 2D-07-03 Lopriore E. 2B-04-01 Lozano M. 2C-05-03 Maitland K. PL-01-01 Mangwana S. 4C-S21-03 Merz EM. 5A-S32-04 Middelburg R.A. 4C-S22-03 Mikkelsen C. 5A-S32-05 Mo A. 3C-TP01-01 Møller A. 4A-S17-02 More N.V. 4A-S17-05 Moss R. 3C-TP01-02 Mulenga J. 4C-S23-01 Müller-Steinhardt M. 3C-S10-01 Muncher L. 4C-S20-03 Narayan		N.	
Langen F. 4D-S26-05 Langi Sasongko P. 3C-S09-01 Larsson L. 3A-S04-04 Läubli H. 4D-S27-01 Lee Y.Q. 4C-S20-01 Lima Pinto B. 3A-S01-05 Lodge L. 2D-07-03 Lopriore E. 2B-04-01 Lozano M. 2C-05-03 Maitland K. PL-01-01 Mangwana S. 4C-S21-03 Merz EM. 5A-S32-04 Middelburg R.A. 4C-S22-03 Mikkelsen C. 5A-S32-05 Mo A. 3C-TP01-01 Møller A. 4A-S17-02 More N.V. 4A-S17-05 Moss R. 3C-TP01-02 Mulenga J. 4C-S23-01 Müller-Steinhardt M. 3C-S10-01 Muncher L. 4C-S20-03 Narayan S. 5A-S30-02 Neubling </td <td></td> <td>W.</td> <td></td>		W.	
Langi Sasongko P. 3C-S09-01 Larsson L. 3A-S04-04 Läubli H. 4D-S27-01 Lee Y.Q. 4C-S20-01 Lima Pinto B. 3A-S01-05 Lodge L. 2D-07-03 Lopriore E. 2B-04-01 Lozano M. 2C-05-03 Maitland K. PL-01-01 Mangwana S. 4C-S21-03 Merz EM. 5A-S32-04 Middelburg R.A. 4C-S22-03 Mikkelsen C. 5A-S32-05 Mo A. 3C-TP01-01 Møller A. 4A-S17-02 More N.V. 4A-S17-05 Moss R. 3C-TP01-02 Mulenga J. 4C-S23-01 Müller-Steinhardt M. 3C-S10-01 Muncher L. 4C-S20-03 Narayan S. 5A-S30-02 Neubling C.M. 4A-S18-01 Nogues	Langen	F.	
Larsson L. 3A-S04-04 Läubli H. 4D-S27-01 Lee Y.Q. 4C-S20-01 Lima Pinto B. 3A-S01-05 Lodge L. 2D-07-03 Lopriore E. 2B-04-01 Lozano M. 2C-05-03 Maitland K. PL-01-01 Mangwana S. 4C-S21-03 Merz EM. 5A-S32-04 Middelburg R.A. 4C-S22-03 Mikkelsen C. 5A-S32-05 Mo A. 3C-TP01-01 Møller A. 4A-S17-02 More N.V. 4A-S17-05 Moss R. 3C-TP01-02 Mulenga J. 4C-S23-01 Müller-Steinhardt M. 3C-S10-01 Muncher L. 4C-S20-03 Narayan S. 5A-S30-02 Neubling C.M. 4A-S18-01 Nogues N. 2C-06-02 O'Brien		P	
Läubli H. 4D-S27-01 Lee Y.Q. 4C-S20-01 Lima Pinto B. 3A-S01-05 Lodge L. 2D-07-03 Lopriore E. 2B-04-01 Lozano M. 2C-05-03 Maitland K. PL-01-01 Mangwana S. 4C-S21-03 Merz EM. 5A-S32-04 Middelburg R.A. 4C-S22-03 Mikkelsen C. 5A-S32-05 Mo A. 3C-TP01-01 Møller A. 4A-S17-05 Moss R. 3C-TP01-01 Mulenga J. 4C-S23-01 Müller-Steinhardt M. 3C-S10-01 Muncher L. 4C-S20-03 Narayan S. 5A-S30-02 Nellis M. 3C-S07-02 Neubling C.M. 4A-S18-01 Nogues N. 2C-06-02 O'Brien S. 4A-S18-03	0 0		
Lee Y.Q. 4C-S20-01 Lima Pinto B. 3A-S01-05 Lodge L. 2D-07-03 Lopriore E. 2B-04-01 Lozano M. 2C-05-03 Maitland K. PL-01-01 Mangwana S. 4C-S21-03 Merz EM. 5A-S32-04 Middelburg R.A. 4C-S22-03 Mikkelsen C. 5A-S32-05 Mo A. 3C-TP01-01 Møller A. 4A-S17-02 More N.V. 4A-S17-05 Moss R. 3C-TP01-02 Mulenga J. 4C-S23-01 Müller-Steinhardt M. 3C-S10-01 Muncher L. 4C-S20-03 Narayan S. 5A-S30-02 Nellis M. 3C-S07-02 Neubling C.M. 4A-S18-01 Nogues N. 2C-06-02 O'Brien S. 4A-S18-03			
Lima Pinto B. 3A-S01-05 Lodge L. 2D-07-03 Lopriore E. 2B-04-01 Lozano M. 2C-05-03 Maitland K. PL-01-01 Mangwana S. 4C-821-03 Merz EM. 5A-S32-04 Middelburg R.A. 4C-S22-03 Mikkelsen C. 5A-S32-05 Mo A. 3C-TP01-01 Møller A. 4A-S17-02 More N.V. 4A-S17-05 Moss R. 3C-TP01-01 Mulenga J. 4C-S23-01 Müller-Steinhardt M. 3C-S10-01 Muncher L. 4C-S20-03 Narayan S. 5A-S30-02 Nellis M. 3C-S07-02 Neubling C.M. 4A-S18-01 Nogues N. 2C-06-02 O'Brien S. 4A-S18-03	Lee	ΥO	
Lodge L. 2D-07-03 Lopriore E. 2B-04-01 Lozano M. 2C-05-03 Maitland K. PL-01-01 Mangwana S. 4C-821-03 Merz EM. 5A-832-04 Middelburg R.A. 4C-822-03 Mikkelsen C. 5A-832-05 Mo A. 3C-TP01-01 Møller A. 4A-S17-02 More N.V. 4A-S17-05 Moss R. 3C-TP01-02 Mulenga J. 4C-823-01 Müller-Steinhardt M. 3C-S10-01 Muncher L. 4C-820-03 Narayan S. 5A-S30-02 Neubling C.M. 4A-S18-01 Nogues N. 2C-06-02 O'Brien S. 4A-S18-03			
Lopriore E. 2B-04-01 Lozano M. 2C-05-03 Maitland K. PL-01-01 Mangwana S. 4C-821-03 Merz EM. 5A-S32-04 Middelburg R.A. 4C-S22-03 Mikkelsen C. 5A-S32-05 Mo A. 3C-TP01-01 Moller A. 4A-S17-02 More N.V. 4A-S17-05 Moss R. 3C-TP01-02 Mulenga J. 4C-S23-01 Müller-Steinhardt M. 3C-S10-01 Muncher L. 4C-S20-03 Nellis M. 3C-S07-02 Nellis M. 3C-S07-02 Neubling C.M. 4A-S18-01 Nogues N. 2C-06-02 O'Brien S. 4A-S18-03	Lodge	L.	
Lozano M. 2C-05-03 Maitland K. PL-01-01 Mangwana S. 4C-S21-03 Merz EM. 5A-S32-04 Middelburg R.A. 4C-S22-03 Mikkelsen C. 5A-S32-05 Mo A. 3C-TP01-01 Møller A. 4A-S17-02 More N.V. 4A-S17-05 Moss R. 3C-TP01-02 Mulenga J. 4C-S23-01 Müller-Steinhardt M. 3C-S10-01 Muncher L. 4C-S20-03 Nellis M. 3C-S07-02 Nellis M. 3C-S07-02 Neubling C.M. 4A-S18-01 Nogues N. 2C-06-02 O'Brien S. 4A-S18-03			
Maitland K. PL-01-01 Mangwana S. 4C-S21-03 Merz EM. 5A-S32-04 Middelburg R.A. 4C-S22-03 Mikkelsen C. 5A-S32-05 Mo A. 3C-TP01-01 Møller A. 4A-S17-02 More N.V. 4A-S17-05 Moss R. 3C-TP01-02 Mulenga J. 4C-S23-01 Müller-Steinhardt M. 3C-S10-01 Muncher L. 4C-S20-03 Narayan S. 5A-S30-02 Nellis M. 3C-S07-02 Neubling C.M. 4A-S18-01 Nogues N. 2C-06-02 O'Brien S. 4A-S18-03			
Mangwana S. 4C-S21-03 Merz EM. 5A-S32-04 Middelburg R.A. 4C-S22-03 Mikkelsen C. 5A-S32-05 Mo A. 3C-TP01-01 Møller A. 4A-S17-02 More N.V. 4A-S17-05 Moss R. 3C-TP01-02 Mulenga J. 4C-S23-01 Müller-Steinhardt M. 3C-S10-01 Muncher L. 4C-S20-03 Narayan S. 5A-S30-02 Nelbling C.M. 4A-S18-01 Nogues N. 2C-06-02 O'Brien S. 4A-S18-03			
Merz EM. 5A-S32-04 Middelburg R.A. 4C-S22-03 Mikkelsen C. 5A-S32-05 Mo A. 3C-TP01-01 Møller A. 4A-S17-02 More N.V. 4A-S17-05 Moss R. 3C-TP01-02 Mulenga J. 4C-S23-01 Müller-Steinhardt M. 3C-S10-01 Muncher L. 4C-S20-03 Narayan S. 5A-S30-02 Nellis M. 3C-S07-02 Neubling C.M. 4A-S18-01 Nogues N. 2C-06-02 O'Brien S. 4A-S18-03	Mangwana	S	
Middelburg R.A. 4C-S22-03 Mikkelsen C. 5A-S32-05 Mo A. 3C-TP01-01 Møller A. 4A-S17-02 More N.V. 4A-S17-05 Moss R. 3C-TP01-02 Mulenga J. 4C-S23-01 Müller-Steinhardt M. 3C-S10-01 Muncher L. 4C-S20-03 Narayan S. 5A-S30-02 Neullis M. 3C-S07-02 Neubling C.M. 4A-S18-01 Nogues N. 2C-06-02 O'Brien S. 4A-S18-03	0	EM.	
Mikkelsen C. 5A-S32-05 Mo A. 3C-TP01-01 Møller A. 4A-S17-02 More N.V. 4A-S17-05 Moss R. 3C-TP01-02 Mulenga J. 4C-S23-01 Müller-Steinhardt M. 3C-S10-01 Muncher L. 4C-S20-03 Narayan S. 5A-S30-02 Nellis M. 3C-S07-02 Neubling C.M. 4A-S18-01 Nogues N. 2C-06-02 O'Brien S. 4A-S18-03			
Mo A. 3C-TP01-01 Møller A. 4A-S17-02 More N.V. 4A-S17-05 Moss R. 3C-TP01-02 Mulenga J. 4C-S23-01 Müller-Steinhardt M. 3C-S10-01 Muncher L. 4C-S20-03 Narayan S. 5A-S30-02 Nellis M. 3C-S07-02 Neubling C.M. 4A-S18-01 Nogues N. 2C-06-02 O'Brien S. 4A-S18-03			
More N.V. 4A-S17-05 Moss R. 3C-TP01-02 Mulenga J. 4C-S23-01 Müller-Steinhardt M. 3C-S10-01 Muncher L. 4C-S20-03 Narayan S. 5A-S30-02 Nellis M. 3C-S07-02 Neubling C.M. 4A-S18-01 Nogues N. 2C-06-02 O'Brien S. 4A-S18-03			
More N.V. 4A-S17-05 Moss R. 3C-TP01-02 Mulenga J. 4C-S23-01 Müller-Steinhardt M. 3C-S10-01 Muncher L. 4C-S20-03 Narayan S. 5A-S30-02 Nellis M. 3C-S07-02 Neubling C.M. 4A-S18-01 Nogues N. 2C-06-02 O'Brien S. 4A-S18-03	Møller	Α.	4A-S17-02
Mulenga J. 4C-S23-01 Müller-Steinhardt M. 3C-S10-01 Muncher L. 4C-S20-03 Narayan S. 5A-S30-02 Nellis M. 3C-S07-02 Neubling C.M. 4A-S18-01 Nogues N. 2C-06-02 O'Brien S. 4A-S18-03		N.V.	
Müller-Steinhardt M. 3C-S10-01 Muncher L. 4C-S20-03 Narayan S. 5A-S30-02 Nellis M. 3C-S07-02 Neubling C.M. 4A-S18-01 Nogues N. 2C-06-02 O'Brien S. 4A-S18-03	Moss	R.	3C-TP01-02
Müller-Steinhardt M. 3C-S10-01 Muncher L. 4C-S20-03 Narayan S. 5A-S30-02 Nellis M. 3C-S07-02 Neubling C.M. 4A-S18-01 Nogues N. 2C-06-02 O'Brien S. 4A-S18-03	Mulenga	J.	4C-S23-01
Narayan S. 5A-S30-02 Nellis M. 3C-S07-02 Neubling C.M. 4A-S18-01 Nogues N. 2C-06-02 O'Brien S. 4A-S18-03		M.	3C-S10-01
Nellis M. 3C-S07-02 Neubling C.M. 4A-S18-01 Nogues N. 2C-06-02 O'Brien S. 4A-S18-03	Muncher	L.	4C-S20-03
Nellis M. 3C-S07-02 Neubling C.M. 4A-S18-01 Nogues N. 2C-06-02 O'Brien S. 4A-S18-03	Naravan		
Neubling C.M. 4A-S18-01 Nogues N. 2C-06-02 O'Brien S. 4A-S18-03		M.	3C-S07-02
Nogues N. 2C-06-02 O'Brien S. 4A-S18-03	Neubling	C.M.	
O'Brien S. 4A-S18-03			
		S.	
Ouwenand W. PL-02-01	Ouwehand	W.	PL-02-01

Ou-Yang	J.	3A-S05-03
Owusu-Ofori	S.	5A-S30-03
Pate	L.	4A-S18-02
Pavenski	K.	4A-S17-01
Pehlic	V.	4C-S24-03
Petermann	R.	4D-S25-04
Peterson	D.	3D-S14-02
Peyrard	T.	4C-S20-05
Pillonel	J.	3D-S13-02
Pirenne	F.	1B-02-01
Pisacka	M.	5A-S29-04
Pistorius	C.	4D-S26-02
Politis	C.	3D-S12-03
Preynat-Seauve	Ο.	3A-S03-01
Ру	JY.	4C-S24-05
Raivola	V.	2A-01-03
Ramirez-Arcos	S.	3A-S04-02
Raos	M.	4A-S16-04
Raud	L.	3C-S09-06
Ree	I.M.C.	3A-S01-04
Reynolds	C.	4A-S18-05
Ricci Hagman	J.	4C-S20-06
Riganò	R.	3D-S11-03
Rigas	A.S.	3D-S15-02
Rong	Χ.	3C-S08-05
Roubinian	N.	PL-02-03
Roulis	E.	3C-S06-02
Ruefli	T.	3A-S05-05
Russell	W.A.	3D-S15-03
Scharberg	E.A.	5A-S29-05
Schöfl	G.	3C-S06-01
Schrezenmeier	H.	1C-03-02
Semple	J.W.	4A-S16-02
Sontakke	P.B.	4C-S21-04
Sozmen	N.N.	5A-S32-02
Spekman	M.L.	3C-S10-02
Spencer	B.R.	3D-S15-04
Spreafico	M.	3C-S08-04
Syrjälä	M.	3D-S14-01

Szittner Teixeira Rodrigues Thonier Tinguely Townsend Trompeter Tzounakas van den Berg van den Hurk van der Schoot van Kraaij	Z. F. V. C. M. S. V. K. K. C.E.		5A-S32-03
van Rosmalen van Weert Vinkenoog Vlaar Vollmer	J. A. M. A. T.	3C-S10-03 4D-S26-03 4A-S19-05 4C-S22-01 2C-05-02	
Vossoughi Vuk Wagner Waldvogel Westhoff	S. T. E.M. S. C.M.	3D-S14-03 4D-S28-04 4D-S26-06 1D-04-03 3A-S02-01	4D 000 05
Whitaker Wiersum Wolkers Worel Wu Yamamoto Yazdanbakhsh Yuen Zaheer Zal Zarghamian Zeerleder Zhao Zwaginga Zwaginga	J.C. M.C. N. P.C. F. K. H.L.A. H.A. F. P. S.S. J.	3A-S01-02 3C-S10-04 4D-S27-03 1A-01-02 3C-S06-04 PL-02-02 3D-S12-01 5A-S30-04 3A-S05-04 PL-03-03 3D-S12-04 3D-S11-01 3C-S09-03 3A-S04-01	4D-S28-05 4A-S19-03
Zykova	S.	4D-S28-02	

	Notes
_	
_	
_	
_	



Could your systems do better to ...?

& Screening Solutions

- · Identify weak phenotypes
- Research platelet transfusion failures
- Get results from ABO problem samples
- Mitigate TRALI

Ask us about...



Blood aenotypina



Antibody screening

Fast & easy to use

- LinkSēg RBC¹
- LinkSēg™ ABO¹
- LinkSēg HPA²
- LinkSēq HLA²
- LABScreen[™] Multi³
- LABType[™] HLA³



- 1. For Research Use Only. Not for use in diagnostic procedures
- 2. For In Vitro Diagnostic Use (Europe only)
- 3. For In Vitro Diagnostic Use

© 2019 Linkage Biosciences Inc. All Rights Reserved.

LinkSeg, LABScreen and LABType are trademarks of Thermo Fisher Scientific Inc.

Thermo Fisher s c | E N T | F | C

Other Information

88

Sunday June 23

17:30 - 18:30 hours

Plenary Room: San Francisco

Opening Ceremony

All delegates and Exhibitors are welcome to attend.

17.00	Welcome address by Martin Classon, 10B1 Fresident
17:38 - 17:48	Welcome address by Rudolf Schwabe and Behrouz Mansouri
	Taleghani, Co-Congress President
17:48 - 17:55	Welcome address by State Councillor Dr. Lukas Engelberger
17:55 - 18:00	Presentation of ISBT Awards and Prizes
	1) ISBT Award
	2) Vox Sanguinis Best Paper Prize
18:00 - 18:20	Entertainment
	Enjoy the Swiss folk music of modern times! Experience different
	musical instruments such as the Alphorn and the Swiss diatonic
	accordion and yodeling Welcome to Switzerland!
18:30	All delegates and Exhibitors are invited to proceed to the
	Welcome Reception in both Exhibition areas

17:30 - 17:38 Welcome address by Martin Olsson, ISBT President

Sunday June 23

18:30 - 21:00 hours Exhibition area 4U and 4.1

Opening of the Trade Exhibition and Welcome Reception

The welcome reception will be held at both Exhibition areas, located in the basement and on the first floor. The reception will permit the delegates to meet old friends and colleagues and make new acquaintances during the evening while enjoying conversations.

During the official opening of the Trade Exhibition there will be entertainment offered at various stands on both exhibition floors:

18:45 - 19:00	1st floor	Ortho Diagnostics (1431)
19:00 - 19:15	Basement	MacoPharma (U302)
19:15 - 19:30	Basement	Wuhan BMS Medicaltech Co., LTD (U123)
19:30 - 19:45	Basement	Bio-Rad (U311)
19:45 - 20:00	1st floor	Immucor (1215)
20:00 - 20:15	Basement	Sato Corporation (U104)



ISBT Run

Tuesday June 25

06:30 - 07:30

All delegates are invited to join for the 5km ISBT Run, departing from and returning to the main entrance of Congress Center Basel. Let's start the day off the best way possible: with a beautiful morning run along the River Rhine. In case you have not pre-registered to participate in the ISBT Run, please come see us at the Service desk in the registration area and receive your running shirt!



Congress Party

Tuesday June 25

19:30 - 23:30

Markthalle

Steinentorberg 20

Price: € 50 per person

Experience our very own, ISBT food festival during the congress party at the Markthalle.

The Markthalle provides comfortable seating right under the dome where you can eat, drink and enjoy refreshments in a unique setting. Let your senses be surprised by the smell of fresh bread, sweet fruits, homemade antipasti, delicious baguettes and pizza's, as well as Asian and Oriental delicacies served by a wide variety of international market stalls.

Catch up with your fellow delegates and dance the night away or sit back in one of the lounge areas. A great opportunity to expand your network and let the congress sink in!

The Markthalle is conveniently located near the train station. With your public transportation ticket, you can take almost every tram to this wonderful location.

Still want to buy a ticket? Come visit us at the Service desk in the registration area.



Ortho Clinical Diagnostics



Be part of the change, visit booth #1431

www.orthoclinicaldiagnostics.com

Satellite Symposia

Satellite Symposium

Monday, June 24

12:30 - 13:30 hours Room: Boston

Immucor

Solving transfusion challenges with specialty products.

Laboratory activities have been converging to routine assays and more standardization for the last decade and in the meantime, manufacturers have been discontinuing low sales products. But in this changing environment, some niche products have emerged because they are THE only solution to solve complex cases.

Laboratory experts are going to share examples and case studies

Kerry Dowling

Blood Transfusion Laboratory Manager – Laboratory Medicine – Southampton General Hospital (UK)

Dr. Antonella Matteocci Head of Red Cell and Platelet Immunohematology Laboratory of Transfusion Medicine Service – S. Camillo Forlanini Hospital – Rome (Italy)

Satellite Symposium

Tuesday, June 25

12:30 - 13:30 hours Room: Boston

Cerus

Safeguarding the blood supply against (re) emerging pathogens Balancing blood safety and economics

Chair: M. Jutzi

Interregionale Blutspende SRK - Bern - Switzerland

12:30 - 12:40 INTRODUCTION

M. Jutzi

Interregionale Blutspende SRK – Bern

- Switzerland

12:40 - 13:00 PROS AND CONS OF TESTING AND

PATHOGEN REDUCTION IN LIGHT OF (RE)

EMERGING PATHOGENS Christoph Niederhauser

Interregionale Blutspende SRK - Bern

Switzerland

13:00 - 13:20 HOW WE PREPARED THE MADRID REGION

FOR A POTENTIAL OUTBREAK OF EMERGING PATHOGENS WITHOUT INCREASING OVERALL PRODUCTION COST Luisa Maria Barea Garcia

Centro de Transfusión de la Comunidad de

Madrid – Spain

13:20 - 13:30 Q&A - DISCUSSION - CONCLUDING

REMARKS

Satellite Symposium

Tuesday, June 25

12:30 - 13:30 hours Room: Sydney

Grifols

DONOR SCREENING AUTOMATION: HOW TO IMPROVE WORKELOW FEELINGY

OPERATIONAL SOLUTIONS THAT DELIVER VALUE Andrew Williams – Managing Partner, Nexus

PROCLEIX PANTHER SYSTEM FEATURING ART Joel Wummer –Director System Engineering, Grifols


IMPROVING EFFICIENCY VIA NEW ASSAY DESIGN: PROCLEIX ULTRIOPLEX E

Jeff Linnen – VP Product Development, Grifols


Notes			

Floor Plan


Floor Plan Ground Floor



Floor Plan Second Floor




Floor Plan Third Floor




Exhibition Floor Plan - Basement

- U111 AABB
- **U131** Agios Pharmaceuticals
- U114 Andreas Hettich GmbH & Co KG
- U113 Angelantoni Life Science S.r.l.
- U118 Applied Science (UK) Ltd.
- U134 Barkey GmbH & Co. KG
- U311 Bio-Rad
- U115 Biolog-id
- U121 Bionic Medizintechnik GmbH
- U130 Changchun Bioxun Biotech Co., Ltd.
- U138 CLST Cryo Life Science Technologies
- U520 Delcon
- U133 Delta T GmbH
- U139 Diagast
- U210 Fresenius Kabi Deutschland GmbH
- U108 GenDx
- U201 Grifols
- U320 Haemokinesis
- U127 Haemonetics
- U125 Helmer Scientific
- U132 Hydrex Diagnostics SP. Z. O.O. SP.K
- U122 Inno-Train Diagnostik GmbH
- U135 Innoopract Informationssysteme GmbH
- U112 IPFAU525 KW Apparecchi Scientific SRL
- U302 Macopharma
- U107 Mallinckrodt Pharmaceuticals (Therakos (UK) Ltd)
- U101 Medinfo International Hemo Service
- U103 Moeller Medical Gmbh
- U422 MTC InvitroU109 Orsense
- U301 Quotient
- U110 Rees Scientific
- U501 Roche
- U137 Sarstedt AG & Co. KG
- **U104** SATO CORPORATION
- U120 Stratec Biomedical UK Ltd
- **U106** Timestrip
- U123 Wuhan BMS Medicaltech Co., LTD



Exhibition Floor Plan - First Floor

- 1311 Abbott
- 1311 Abbott
- 1242 Actium Products and systems
- 1143 Ashland
- 1141 B Medical Systems
- 1403 Best Theratronics
- 1129 BioMerieux
- 1301 Cerus Europe
- 1322 Conrov
- 1322 Conroy
- 1221 Council of Europe, EDQM
- 1345 CTC Diagnostics
- 1321 Demophorius Healthcare
- 1353 EXPERTMED SRL
- 1115 Fujirebio Inc
- 1355 Gamma-Service Medical GmbH
- 1155 GFE Blut
- 1343 Gilardoni SPA
- 1401 Global Blood Fund
- 1411 HemoCue AB
- 1324 ICCBBA
- 1215 Immucor
- 1404 Kawasumi Laboratories, Inc.
- 1222 LmB Technologie GmbH
- 1246 M. & G. INT.'L s.r.l.
- 1421 MAK-System
- 1150 Meise GmbH
- 1113 NanoEnTek
- 1431 Ortho Clinical Diagnostics
- 1111 PCS Professional Clinical Software GmbH
- 1243 Rad Source Technologies, Inc.
- 1351 Sanquin Reagents B.V.
- 1323 Scinomed Ltd
- 1127 Sichuan Nigale Biotechnology Co., LTD
- 1245 Sigma Laborzentrifugen GmbH
- 1347 Strub GmbH
- 1402 Sysmex
- 1241 Terumo BCT
- 1412 Thermo Fisher Scientific



PLASMACHECK



PLASMA CHECK SYSTEM is a system able to acquire, store, record and certify the temperature detected at the core of "surrogate" bags during the entire freezing cycle, consistently with GMP requirements.


PLASMA CHECK SYSTEM consists


of 3 parts (Fig. 1):

a) "surrogate" bags (**Check-bags**) of 250 and 700 mL corresponding to the average standard volumes of the real products, containing a fluid validated to simulate the thermal behavior of plasma (*Fig. 2*):

b) a mobile probe (Cryo- Med) positionable at the core of the Check-bags; c) a dedicated software (Memo-Track).

PLASMA CHECK SYSTEM is a valuable system for plasma freezing validation and monitoring, as well as to perform monitoring and control of the whole pathway of frozen plasma in the BE (*Fig.3*). It is a technologically advanced, easy-to-use and cost-effective tool that can efficiently replace other traditional methods commonly used for the abovementioned purposes.





Plasma Check System is patented and commercialized by Expertmed Srl.

Visit us at Stand 1353

